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INTRODUCTION
For many decades, treatment of acute disease or a chronic illness has been mostly
accomplished by delivery of drugs to patients using various pharmaceutical dosage forms
including tablets, capsules, pills, suppositories, creams, ointments, liquids, aerosols, and
injectables as drug carriers.
Drug may be administered by variety of routes but  oral  administration is  adopted
wherever possible. It is safest, easiest, and most economical route of drug administration.
Amongst  drugs  that  are  administered  orally  solid  oral  dosage  forms  i.e.  tablets  and
capsules,  represent  the  preferred  class  of  products.  Out  of  the  two oral  solid  dosage
forms, the tablets have number of advantages like tamper proof, low cost, and speed of
manufacturing  (direct  compression),  ease  of  administration,  patient  compliance,  and
flexibility in formulation etc.
The  basic  goal  of  therapy  is  to  achieve  a  steady  state  blood  level  that  is
therapeutically effective and non-toxic for an extended period of time. The design of
proper dosage regimens is an important element in accomplishing this goal. Since there is
increase in cost and compliance involved in the development and marketing of new drug
entities, this has forced most of the pharmaceutical industries to focus their attention on
the development of sustained / controlled / prolonged system.  
Sustained release,  sustained action,  prolonged  action,  controlled  release,  extended
action, timed release, depot and repos  itory dosage forms are terms used to identify drug
delivery  systems  that  are  designed  to  achieve  a  prolonged  therapeutic  effect  by
continuously releasing medication over an extended period of time after administration of
single dose. In the case of injectable dosage forms, this period may vary from days to
months. In the case of orally administered dosage forms, this period is measured in hours
and critically depends on the residence time of the dosage form in the gastrointestinal
tract. The term controlled release has become associated with those systems from which 
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therapeutic agents may be automatically delivered at predetermined rates over a long
period of time. Products of this type have been formulated for oral, injectable and topical
use and inserts for placement in body cavities.
Controlled release also denotes systems which can provide some control whether this
be of  a  temporal  or  spatial  nature  or  both for  drug release  in  the  body.  The  system
attempts  to  control  drug  concentrations  in  the  target  tissues  or  cells.  Prolonged  or
sustained release systems only prolong therapeutic blood or tissue levels of the drug for
an extended period of time6.
Sustained release systems include any drug delivery system that achieves slow release
of  drug  over  an  extended  period  of  time.  If  the  system is  successful  in  maintaining
constant drug levels in the blood or target tissue, it is considered as a controlled-release
system. If it is unsuccessful at this but nevertheless extends the duration of action over
that achieved by conventional delivery,  it is considered as a prolonged release system.
This is illustrated in the following figure-17.
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The  oral  route  of  administration  for  sustained  release  systems  has  received  greater
attention because of more flexibility in dosage form design. The design of oral sustained
release  delivery systems  is  subjected  to  several  interrelated  variables  of  considerable
importance such as the type of delivery system, the disease being treated, the patient, the
length of therapy and the properties of the drug.
1.1 Advantages of Sustained Release Dosage Forms: 
1. The frequency of drug administration is reduced. 
2. Patient compliance can be improved. 
3. Drug administration can be made more convenient as well. 
4. The blood level oscillation characteristic of multiple dosing of conventional dosage 
     forms is reduced. 
5. Better control of drug absorption can be attained, since the high blood level peaks that
    may be observed after administration of a dose of a high availability drug can be 
    reduced. 
 6. The characteristic blood level variations due to multiple dosing of conventional 
      dosage forms can be reduced. 
7. The total amount of drug administered can be reduced, thus: 
• Maximizing availability with minimum dose; 
• Minimize or eliminate local side effects; 
• Minimize or eliminate systemic side effects; 
• Minimize drug accumulation with chronic dosing. 
8. Safety margin of high potency drugs can be increased and the incidence of both local 
    and systemic adverse side effects can be reduced in sensitive patients. 
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9. Improve efficiency in treatment. 
o Cure or control condition more promptly; 
o Improve control of condition i.e., reduce fluctuation in drug level; 
o Improve bioavailability of some drugs; 
o Make use  of  special  effects;  e.g.  sustained  release  aspirin  for  morning
relief of  arthritis by dosing before bed-time. 
10. Economy. 
1.2 Disadvantages of Sustained Release Formulations: 
1. Administration of sustained release medication does not permit the prompt termination of
therapy. 
2. Flexibility in adjustment of dosage regimen is limited. 
3. Controlled release forms are designed for normal population i.e. on the basis of average
drug biologic half-lives. 
4. Economic factors must  also be assessed, since more costly process and equipment are
involved in manufacturing of many controlled release dosage forms. 
1.3 GENERAL PRINCIPLE OF CONTROLLED – RELEASE SYSTEMS
The concept of controlled release systems is to deliver a constant supply of the
active ingredient by continuous release for a certain period of time, an amount of the drug
equivalent to that eliminate by the body.
The following model has shown the three major processes involved in controlled-
release systems in
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Figure -2.
                        
                     Kr                               Ka       Ka                                    Ke      
Tablets, Capsules, GIT, Skin surface,
Transdermal patches, Oral cavity, Vagina,
Inserts, Implants, etc. Rectum, etc.
                    Release                            Absorption                              Elimination
The kinetics of drug release will be dependent on the specific prolonged action
mechanism utilized  in  manufacturing  the  controlled  release  system.   Calculations  of
amount of drug needed in the sustained release component can be accomplished in a
following relationship.
Rate of drug input =Rate of drug output8 ----------------- (1)
1. If it is considered that elimination is generally first order process, then
Rate of drug output = D Ke ----------------- (2)
When D is the maintenance dose, Ke is the first order rate constant of elimination.
The value of Ke can be obtained if the biological half-life drug is known
Ke = 0.693/t1/2 - ---------------- (3)
Therefore, the rate of drug out put after administering a single dose, D, can be calculated
from equation.
Rate of drug out put  =  0.693 (D) ----------------- (4)       
                                         t1/2    
Substitute for Eq – 4 in Eq – 1, we have
Rate of drug input =        0.693 (D) ----------------- (5) 
                                                 t1/2    
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Thus, in order to calculate the amount of drug needed in the sustained component
to represent the dose require for administration at every T hr of dosing intervals, we can
multiply Eq-5 by
Amount of drug needed in =     0.693(D)T   ----------------- (6)
             the sustained component                        t1/2   
1.3.1 Release Rate and Dose Consideration9
Conventional  dosage  forms include solutions,  capsules,  tablets,  emulsions,  etc.
These  dosage  forms  can  be  considered  to  release  their  active  ingredients  into  an
absorption pool immediately.
                        Kr                                               Ka                                                            Ke
Dosage form                     Absorption pool                              Target area
            Drug                                     absorption                            elimination
                       Release   
Where,
 Kr = First order rate constant for drug release.
Ka    = First order rate constant for drug absorption.
Ke    = First order rate constant for overall drug elimination.
• For  immediate  release  dosage  forms  Kr>>>  Ka or  alternatively
absorption of drug across a biological membrane is the rate-limiting
step in delivery of the drug to its target area.
• For non-immediate release dosage forms, Kr <<<Ka, that is, release of
drug from the dosage form is the rate limiting step.  This cause the
above kinetics scheme to reduce to   
                                                                 Kr                                       Ke
Dosage form                            Target area
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Thus, the effort  to develop a delivery system that release drug slowly must be
directed primarily at altering the release rate by affecting the value of Kr.  The ideal goal
in designing a controlled-release system is to deliver drug to the desired site at a rate
according to needs of the body, i.e. a self-regulated system based on feedback control but
this is a difficult assignment.
1.4 Terminology10:
Controlled drug delivery or modified release delivery systems may be defined as
follows:-
1.4.1 Controlled – Release formulation:
The  controlled  release  system  is  to  deliver  a  constant  supply  of  the  active
ingredient, usually at a zero-order rate, by continuously releasing, for a certain period of
time, an amount of the drug equivalent to the eliminated by the body.  An ideal controlled
drug delivery system is the one, which delivers the drugs at a predetermined rate, locally
or systemically, for a specific period of time.
1.4.2 Repeat action preparations:
A dose of the drug initially is released immediately after administration, which is
usually equivalent to a single dose of the conventional drug formulation.  After a certain
period of time, a second single dose is released.  In some preparation, a third single dose
is  released  after  a  certain  time  has  elapsed,  following  the  second  dose.   The  main
advantage is that it provides the convenience of supplying additional dose(s) without the
need of re-administration.  It has disadvantage that the blood levels still exhibit the “Peak
and valley” characteristic of conventional intermittent drug therapy.
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1.4.3 Extended-Release formulations:
Extended-Release formulations are usually designed to reduce dose frequency and
maintain relatively constant or flat plasma drug concentration.  This helps avoid the side
effects associated with high concentration.
1.4.4 Delayed release preparations:
The drug is released at a later time after administration.  The delayed action is
achieved by the incorporation of a special coat, such as enteric coating,  or other time
barriers  such  as  the  formaldehyde  treatment  of  soft  and  hard  gelatin  capsules.   The
purposes of such preparations are to prevent side effects related to the drug presence in
the stomach, protect the drug from degradation in the highly acidic pH of the gastric fluid.
1.4.5 Site specific targeting:
These systems refer to targeting of a drug directly to a certain biological location.
In this case the target is adjacent to or in the diseased organ or tissue.
1.4.6 Receptor targeting:
These systems refer to targeting of a drug directly to a certain biological location.
In this case the target is the particular receptor for a drug with in organ or tissue.  Site
specific targeting and receptor targeting systems satisfy the spatial aspect of drug delivery
and are also considered to be controlled drug delivery systems.
1.5 PHYSICO-CHEMICAL FACTORS INFLUENCING ORAL CONTROLLED 
RELEASE DOSAGE FORM11: 
1.5.1 Dose size: 
For orally administered systems, there is an upper limit to the bulk size of the
dose to be administered. In general a single dose of 0.5 to 1 gm is considered maximal. 
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1.5.2 Ionization, pKa and aqueous solubility: 
The pH partition  hypothesis  simply states  that  the  unchanged  form of  a  drug
species  will  be  preferentially  absorbed  through  many  body  tissues  therefore  it  is
important  to  note  the  relationship  between  pKa  of  the  compound  and  its  absorptive
environment. For many compounds the site of maximum absorption will also be the area
in which the drug is least soluble. For conventional dosage forms the drug can generally
fully dissolve in the stomach and then be absorbed in the alkaline pH of the intestine. For
dissolution  of  diffusion  controlled  forms,  much of  the  drug  will  arrive  in  the  small
intestine in solid form.  This means that  the solubility of the drug is  likely to change
several orders of magnitude during its release. 
1.5.3 Partition coefficient: 
The compounds with a relatively high partition coefficient are predominantly lipid
soluble and easily penetrate membranes resulting high bioavailability. Compounds with
very low partition coefficient  will  have difficulty in  penetrating membranes  resulting
poor bioavailability. Further more partitioning effects apply equally to diffusion through
polymer membranes
1.5.4 Drug Stability: 
Drugs that are unstable in the stomach can be placed in a slowly soluble form or have
their release delayed until they reach the small intestine However, such a strategy would be
detrimental for drugs that either are unstable in the small intestine or undergo extensive gut
wall  metabolism,  as  pointed  out  in  the  decreased bioavailability  of  some anticholinergic
drugs from controlled /sustained release formulations.
1.5.5 Protein Binding : 
It  is well  known that  many drugs bind to plasma proteins with a concomitant
influence on the duration of drug action. Since blood proteins are for the most part 
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recirculated and not eliminated, drug protein binding can serve as a depot for drug
producing a prolonged release profile, especially if a high degree of drug binding occurs. 
Levine has shown that quarternary ammonium compounds bind to mucin in the GIT.
Drug bound to mucin may act as depot and act as a sustained release product.
1.6 BIOLOGICAL FACTORS INFLUENCING ORAL SUSTAINED RELEASE
DOSAGE FORM: 
1.6.1 Biological Half Life: 
Therapeutic  compounds  with  short  half-lives  are  excellent  candidates  for
controlled release preparations. Drug with very short  half-life will require excessively
large amounts of drug in each dosage unit to maintain controlled effects, thus forcing the
dosage form itself to become too large to be administered. Compounds with relatively
long half lives, generally greater than 8 hours are generally not used in controlled release
dosage forms since their effect is already sustained and also GI transit time is 8-12 hrs. 
Drugs  with  short  half-lives  require  frequent  dosing  in  order  to  minimize
fluctuations in blood levels accompanying conventional oral dosage regimens. Therefore
controlled release dosage forms would appear very desirable for drugs. 
Infact sustained release formulations of prednisolone sodium phosphate, a methyl
prednisolone have been shown to be equally effective as conventional tablets, offering no
advantages over the latter.
1.6.2 Absorption: 
The characteristics of absorption of a drug can greatly affect its suitability as a
controlled release product. Assuming the transit time of most drugs and devices in the
absorptive regions before release is complete. The absorption rate constant is an apparent
rate constant. It should in actuality be the release rate constant of the drug from dosage
form. 
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1.6.3 Metabolism:
Drugs  that  are  significantly  metabolized  especially  in  the  region  of  the  small
intestine can show decreased bioavailability from slower releasing dosage forms. This is
due to saturation of intestinal wall enzyme systems.
TABLE 1
Classification of Sustained/Controlled Release Systems12
Type of system Rate-control mechanism
Diffusion controlled
 Reservoir system
 Monolithic system
       
        Diffusion through membrane
Water penetration controlled
 Osmotic system
 Swelling system
- transport of water through semipermeable membrane
- water penetration into glossy polymer
Chemical controlled
 Monolithic system
 Pendant system
 Ion exchange resins
- Surface erosion or bulk erosion
- Hydrolysis of pendent group and diffusion from bulk
polymer
-Exchange  of  acidic  or  basic  drugs  with  the  ions
present on resins.
Regulated system
 Magnetic, Ultrasound -  External application of magnetic field or ultrasound
to device
                                                                                          INTRODUCTION 
Padmavathi College Of Pharmacy And Research Institute Page 11
Oral sustained release products have gained importance because of the technological
advances, which help achieve zero order release rate of the therapeutic substances. It is
not possible to get an ideal sustained effect where the drug is given orally because the
rate processes are influenced grossly by a number of factors viz.13
 Variations in pH of the gastro-intestinal tract
 Gastric motility
 Nature of fluid
 Fluid volume and content of gastrointestinal tract
 Health and disease
 In-vivo dissolution rate and consequence bioavailability.
 In the recent years, considerable attention has been focused on the development of
controlled drug delivery systems for  convenience  and ambulatory patient  compliance,
which is a problem normally,  associated with some class of drug such as nonsteroidal
anti-inflammatory, anti-hypertensive, anti-asthmatic and antipyretic drugs. Among all the
methods,  matrix  dissolution  controlled  using  swellable  hydrophilic  gums  have  been
extensively investigated.14
Polymers  are  used  to  control  the  release  of  drugs  from  different  dosage  forms
administered orally.14 An ideal matrix formulation should contain polymers and diluents
at amount as little as possible as well as releasing its content in a sustained release profile
over a reasonable length of time and preferably with a zero order kinetics.15
Controlled release systems provide drug release in an amount sufficient to maintain
the  therapeutic  drug  level  over  extended  period  of  time,  with  the  release  profiles  of
predominantly  controlled  by  the  special  technological  construction  and  design  of  the
system itself. The release of the active constituent is therefore, ideally independent of
exterior factors. In case of sustained release dosage forms the release of the active agents,
although, is lower than in the conventional formulations, however it is still substantially 
                                                                                          INTRODUCTION 
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affected by the external environments into which it is going to be released. Extended
release dosage forms are those due to special  technology of the preparation provides,
soon after a single dose administration, therapeutic drug level maintained for 8-12 hours;
while long or prolong action products are dosage forms containing chemically modified
therapeutic substances in order to prolong biological half-live.16
However, the release behavior is inherently non-linear in nature, with continuously
diminishing release rate due to diffusional resistant and / or a decrease in effective area at
the  diffusion  front.  With  the  growing  need  for  optimization  therapy,  matrix  system
providing programmable rate of delivery other than the typical first order delivery, are
becoming more important. For this reason, constant rate delivery has been one of the
primary  targets  of  controlled  release  system,  especially  for  drug  with  a  narrow
therapeutic  index.  Considerable  efforts  have  been  made  and  are  being  continued  to
develop new drug concepts in order to achieve zero-order or near to zero-order release
kinetics. To alter the kinetics of drug release from inherent non-linear behavior, scientists
have exploited the use of some matrices with erosion, diffusion and swelling controlled
mechanisms, as well as matrix membrane combination concepts, during research work. 16
Different types of matrices used as oral sustained release drug delivery system i.e. 16
 Hydrophobic matrix tablets
 Hydrophilic swellable matrix 
 Floating type drug delivery system (gastro retentive drug delivery system)
 Complex reservoir or multi layered matrix
 Bioadhasive or mucoadhesive drug delivery system
 Beads
 Pellets
 Microcapsules and micro tablets
                                                                                          INTRODUCTION 
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 Among various technologies available, monolithic matrices continue to be popular 
because of simplicity in processing technology required, reproducibility and stability of 
the materials and dosage forms as well as ease of scale-up operation. The main potential 
disadvantage of the matrix system is the lack of zero-order release kinetics due to time 
dependent changes in drug depleted matrix surface area and diffusional path length. In 
order to achieve linear (zero-order) release, various strategies that seek to manipulate 
tablet structure or geometry have been developed.17
Polymers  are  used  to  control  the  release  of  drugs  from  different  dosage  forms
administered orally. The value of hydrophilic, polymer based matrix system as carriers
for controlled release delivery is well recognized and increasingly demonstrated by the
numerous  patents,  research  paper,  and  U.S.  food  and  drug  administration  (FDA)-
approved  matrix  based  product.  In  particular,  water-soluble  cellulose  ether  [e.g.
hydroxypropylmethylcellulose  (HPMC)  and  hydroxypropylcellulose  (HPC)],
polyethylene  oxide,  polyvinyl  alcohols, carbopol  and polysaccharides  such as xanthan
gum, chitosan, alginic acid, pectin and guar gum have been extensively used.17
1.7 Physicochemical factors influencing oral sustained-release dosage form design
1.7.1 Dose Size:
In general, single dose of 0.5 – 1.0 g is considered maximal for a conventional dosage
form. This also holds true for sustained-release dosage forms. Another consideration is
the margin of safety involved in administration of large amounts of drug with a narrow
therapeutic range. 
1.7.2  Ionization, pKa, and aqueous solubility: 
Most drugs are weak acids or bases. Since the unchanged form of a drug preferentially
permeates across lipid membranes, it is important to note the relationship between the
pKa  of  the  compound  and  the  absorptive  environment.  Delivery  systems  that  are
dependent on diffusion or dissolution will likewise be dependent on the solubility of drug
in the aqueous media. For dissolution or diffusion sustaining forms, much of the drug will
arrive in the small intestine in solid form, meaning that the solubility of the drug may
change several orders of magnitude during its release. The lower limit for the solubilityof
a drug to be formulated in a sustained release system has been reported to be 0.1 mg/ml.
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1.7.3  Partition coefficient:
Compounds with a relatively high partition coefficient are predominantly lipid-soluble
and, consequently, have very low aqueous solubility. Furthermore these compounds can
usually  persist  in  the  body  for  long  periods,  because  they  can  localize  in  the  lipid
membranes of cells.
1.7.4 Stability: 
Orally administered drugs can be subjected to both acid-base hydrolysis and enzymatic
degradation. For drugs that are unstable in the stomach, systems that prolong delivery
over  the  entire  course  of  transit  in  the  GI  tract  are  beneficial.  Compounds  that  are
unstable  in  the  small  intestine  may  demonstrate  decreased  bioavailability  when
administered from a sustaining dosage form. 53
1.8 Drug selection for oral sustained release drug delivery systems 54
The biopharmaceutical evaluation of a drug for potential use in controlled release drug
delivery system requires knowledge on the absorption mechanism of the drug from the G.
I. tract, the general absorbability, the drug’s molecular weight, solubility at different pH
and apparent partition coefficient.
Table 2: Parameters for drug selection
Parameter Preferred value
Molecular weight/ size < 1000
Solubility > 0.1 mg/ml for pH 1 to pH 7.8
Apparent partition coefficient High
Absorption mechanism Diffusion
General absorbability From all GI segments
Release
Should not be influenced by pH and 
enzymes
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The pharmacokinetic evaluation requires knowledge on a drug’s elimination half- life,
total clearance, absolute bioavailability, possible first- pass effect, and the desired steady
concentrations for peak and through.
1.8.1 Basic kinetics of controlled drug delivery 55
In order to establish a basis for discussion of the influence of drug properties and the
route of administration on controlled drug delivery,  following mechanisms need a fair
mention, 
• Behavior of drug within its delivery systems 
• Behavior of the drug and its delivery system jointly in the body.
The  first  of  the  two  elements  basically  deal  with  the  inherent  properties  of  drug
molecules, which influence its release from the delivery system.  For conventional 
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systems, the rate-limiting step in drug availability is usually absorption of drug across a
biological membrane such as the gastro intestinal wall.
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Table 3: Pharmacokinetic parameters for drug selection
Parameter Comment
Elimination half life Preferably between 0.5 and 8 h
Total clearance Should not be dose dependent
Elimination rate constant Required for design
Apparent volume of distribution
Vd
The larger Vd and MEC, the larger will be
the required dose size.  
Absolute bioavailability Should be 75% or more
Intrinsic absorption rate Must be greater than release rate
Therapeutic  concentration  Css
av
The lower Css av and smaller Vd, the loss
among of drug required
Toxic concentration Apart the values of MTC and MEC, safer
the dosage form. Also suitable for drugs
with very short half-life.
However,  in sustained/controlled release product, the release of drug from the dosage
form is the rate limiting instead; thus, drug availability is controlled by the kinetics of
drug release than absorption.  
1.9 TECHNIQUES FOR PREPARATION OF CONTROLLED RELEASE 
FORMULATION: 
1.9.1 BARRIER COATING: 
The barrier coating principle can be applied to either beads or granules or to the
whole tablet.  If  barrier  coated granules  or  beads  are used,  usually one portion of  the
granules containing the drug is uncoated for the dosage form, and the rest of the granules
are coated, whereby different fractions may be done with different numbers of coats in
order to get controlled release. The uncoated and coated beads or granules can either be
filled in to a hard gelatin capsules or they can be compressed into a tablet. The coating
material may be fats, waxes or plastic materials. The release mechanism is generally by
diffusion or in some case erosion. 
1.9.2 MATRIX EMBEDMENT: 
In  this  method  drug  is  dispersed  in  a  matrix  of  material,  which  may  be
encapsulated in particulate form or compressed into tablets. Release is controlled by a
combination  of  several  processes.  These  include  permeation  of  the  matrix  by  water,
leaching of the drug from the matrix or erosion of matrix material. 
Three classes of retardant materials are used to prepare matrix tablet formulations. 
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1) Water insoluble, inert materials, the examples in this class includes polyethelene,
polyvinyl chloride, methyl acrylate-methacrylate copolymer, ethyl cellulose.
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2) Insoluble, erodible materials, the examples in this class include stearyl  alcohol,
stearic acid, polyethylene glycol.
3) Hydrophilic materials, the examples in this class include Hydroxy propyl methyl
cellulose,  sodium CMC,  sodium alginate  etc.,  Matrix  systems  are  also  called
Monolithic  devices.  In  a  monolithic  device  the  therapeutic  agent  is  intimately
mixed in a rate controlling polymer, and release occurs by diffusion of the agent
from the device. Two types of devices can be considered; one in which the active
agent  is  dissolved  in  the  polymer,  whereas  in  the  other  the  active  agent  is
dispersed in the polymer. 
1.9.3 Preparation of Matrix devices 8: 
1. Matrix tablets can be prepared by the usual tablet compression method. The polymers
as well as the drug are mixed intimately and granulated with a granulating fluid (water
or alcohol) and the granules can then be compressed into tablets. 
2.  Molding: In  this procedure the polymer  and drug mixture is  forced  to  flow into a
closed container having the desired shape by the application of heat and pressure. The
closed container is known as the mold. Two types of molding procedure are used. 
a)  Compression  molding:  In  this  procedure,  the  polymer  and  drug  mixture  is
placed in the lower half of a heated mold, the mold is closed, air and excess
mixture  are  forced  out  and  final  pressure  is  applied  for  the  selected  time
period. 
b) Injection molding: In  this procedure,  the mixture is first preheated and then
forced into a cold mold cavity by means of a hydraulic plunger at pressures
ranging between 10,000 psi and 30,000 psi.  
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3. Extrusion: In this process, polymer is continuously propelled along a screw through
regions of high temperature and pressure where it is melted and compacted and finally
forced through a die to give the final shape. 
4. In this procedure the polymer and drug mixture is dissolved in a suitable solvent to
form a viscous solution that is then spread on a flat, non-adhesive surface; then the
solvent slowly evaporates. The resultant polymer is then peeled and milled and the
granules are then compressed into tablets. 
5. Polymerization in Situ: In this procedure a liquid polymer or a prepolymer is used and
drug is dispersed in it. By using a polymerizing agent, the monomer drug mixture is
polymerized in a suitable mold. 
1.10 MECHANISM OF DRUG RELEASE FROM MATRIX DEVICES: 
                        1.10 DISSOLUTION CONTROLLED RELEASE: 
Controlled release oral products employing dissolution as the rate limiting step are in
principle simplest to prepare. Even if a drug has a rapid rate of dissolution it is possible to
incorporate it into a tablet with a carrier, that has a slow rate of dissolution. 
We can assume the dissolution process where the rate of diffusion from the solid surface
to the bulk solution through an unstirred liquid film is the rate limiting step. In this case
the  dissolution  process  at  steady  state  would  be  described  by  the  Noyes-Whitney
equation. 
dc/dt = KD A(Cs – C) -------------------------- (1) 
dc/dt is the dissolution rate
KD is the dissolution rate constant 
Cs is the saturation solubility of the drug and 
C is the concentration of drug in the bulk of the solution. 
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In relation to diffusion expression that KD equals D / V.I. Where ‘D’ is the diffusion
coefficient,  ‘V’  is  the volume of  the  dissolution medium and ‘I’  is  the thickness  of  the
unstirred liquid film. 
From the above expression it can be seen that the rate of dissolution i.e., availability
is  approximately proportional  to  the  solubility of  the  drug in  the  dissolution media  (Cs)
provided constant area and diffusional path length are maintained. 
This equation predicts  constant  dissolution rate  as  long as  enough drug is  present  to
maintain Cs  constant and provided surface area does not change. For spherical particles
the change in area can be related to weight of the particle and substituted in the diffusion
equation to give and expression that relates dissolution to the weight remaining (W). 
Wo1/3 – W1/3 = K1D ------------------------ (2) 
Wo is the initial weight. 
K1D is the cube root dissolution expression. 
The above equation described dissolution rate of spherical particles when surface
area and diffusional path length are changing. 
The common forms of dissolution control formulations fall into two categories. 
(a) Encapsulation dissolution control. 
(b) Matrix dissolution control. 
(a)Encapsulation dissolution control: 
These methods generally involve coating individual particles or granules of drug
with a slowly dissolving material. The coated particles can be compressed directly into
tablets  as  in  spacetabs  or  placed  in  capsules  as  in spansule products.  Since the time
required for dissolution of the coat is a function of thickness and aqueous solubility, one
can obtain repeat or sustained action by employing a narrow or a wide spectrum of coated
articles of varying thickness respectively. 
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(b)Matrix dissolution control: 
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This method involve compressing the drug with a slowly dissolving carrier into a
tablet form. Here the rate of drug availability is controlled by the rate of penetration of
the dissolution fluid into the matrix. This in turn can be controlled by porosity of the
tablet  matrix,  the presence of hydrophobic  additives  and the wettability of tablet  and
particle surface. 
1.10.2 DIFFUSION CONTROLLED RELEASE: 
Diffusion controlled release products are basically of two types. 
a. Encapsulated diffusion control: 
In this system water insoluble polymeric material encases a core of drug. Drug will
partition into the membrane and exchange with the fluid surrounding the particles  or
tablet. The rate of drug release is given by equation. 
Dm/dt = A DK C / I ------------------------ (3) 
A is area
D is diffusion coefficient 
K is the partition coefficient of the drug between the membrane and drug core 
‘I’ is the diffusional path length and 
C is the concentration difference across the membrane. 
An important parameter in the above eqn (3) is the partition coefficient which is
defined as the concentration, of the drug in the membrane over the concentration of drug
in the core. If the partition coefficient is high, the core will be depleted of drug in a short
time so that zero order release will be observed only over a short segment of the time
course of drug release. 
To obtain a constant drug release rate all the terms in right hand side of the above
equation must be held constant. 
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Methods to develop reservoir type devices include press coating, air suspension 
coating techniques. Micro encapsulation process is a commonly used procedure to coat the 
drug particles to be incorporated. 
b. Sintering technique: 
Sintering means fusion of particles or formations of welded bonds between particles
of polymer. Controlled release oral dosage forms were developed by sintering the polymer
matrix by exposing to temperature above the glass transition (Tg) point of the polymer or
exposing these matrix systems to solvent vapors. 
The  temperature  treatment  methods  involves  the  exposure  of  the  dosage  form  to
temperature and the polymer  forming the matrix  slowly melts and the welded bonds are
formed  and  this  results  in  the  controlled  release  of  the  active  ingredient.  However  this
method may be applied to only those drugs that are resistance to the temperature exposure
and this may be limiting factor for many drugs that get degraded at elevated temperatures.
Moreover the storage conditions may also affect the drug release from those preparations. 
Tablets prepared from insoluble materials are designed to be ingested intact and not to
break apart in the GI tract. Various release retardant polymers such as hydrophilic polymers
(xanthan gum,rosin gum,locust bean gum etc) and hydrophobic polymers ( Eudragits etc.) are
widely used to control the drug release from the matrix. When the matrix tablet comes in
contact  with biological  fluids,  the hydrophilic  polymers  swell  and form a strong viscous
barrier, thus controlling the drug release. 
The matrix tablet preparation appears to be a most attractive approach from the process 
development and scale-up point of view.
1.11  Factors  influencing  the  in  vivo performance  of  sustained  release  dosage
formulations52
There  are  various  factors  that  can  influence  the  performance  of  a  sustained  release
product. The physiological, biochemical, and pharmacological factors listed below can
complicate the evaluation of the suitability of a sustained release dosage formulation.
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 (a)Physiological
• Prolonged drug absorption
• Variability in GI emptying and motility
• Gastrointestinal blood flow
• Influence of feeding on drug absorption
(b)Pharmacokinetic/ biochemical
• Dose dumping
• First- pass metabolism
• Variability in urinary pH; effect on drug elimination
• Enzyme induction/ inhibition upon multiple dosing
(c)Pharmacological
• Changes in drug effect upon multiple dosing
• Sensitization/ tolerance
 1.12 In vitro evaluation of sustained release formulations
The data is generated in a well-designed reproducible in-vitro test such as dissolution test.
The method should be sensitive enough for discriminating any change in formulation
parameters and lot-to-lot variations. The key elements for dissolution are:
a) Reproducibility of method
b) Proper choice of media 
c) Maintenance of sink conditions 
d) Control of solution hydrodynamics 
e) Dissolution rate as a function of pH ranging from pH 1 to 8 including several
intermediate values preferably as topographic dissolution characterization. 
f) Selection of the most discriminating variables (media, pH rotation speed etc.) as
the basis for dissolution test and specification. 
Ideal  in-vitro method  can  be  utilized  to  characterize  bio-availability  of  the  sustained
release product and can be relied upon to ensure lot-to-lot performance.
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          1.13 INTRODUCTION OF ANTIVIRAL DRUG
Viruses are obligate intracellular parasites that consist of either double- or single-
stranded DNA or RNA enclosed in a protein coat  called a  capsid. Some viruses also
possess a lipid envelope that, like the capsid, may contain antigenic glycoproteins. Most
viruses contain or encode enzymes essential for viral replication inside a host cell, and
they usurp the metabolic machinery of their host cell. The discovery of novel antiviral
inhibitors  often  is  linked  to  a  better  understanding  of  the  molecular  events  in  viral
replication. The stages of viral replication and the classes of antiviral agents could act at
each  stage  of  replication.  Effective  antiviral  agents  inhibit  virus-specific  replicative
events or preferentially inhibit virus-directed rather than host cell-directed nucleic acid or
protein synthesis. However, host cell molecules that are essential to viral replication also
may offer targets for developing new short-term therapies.
Antiviral drugs are classified as following:
• Nonreteroviral drugs
E.g.  Acyclovir,  Cidofovir,  Famciclovir,  Penciclovir,  Ganciclovir,  Idoxuridine,
Amantadine, Interferon, Ribavirin.
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• Antireteroviral drugs
E.g.  Lamivudine,  Zidovudine,  Didanosine,  Zalcitabine,  Stavudine,  Abacavir,
Tenofovir, Nevarapine, Efvirenz, Saqnavir, Ritonavir, Indinavir etc.   
The population of patient with chronic disease or complications of other disease
has recently been increased. These situations necessitate taking drug for a long period and
or multiple medicines simultaneously, which can lead to increase in non-compliance. The
problem would be worse for drugs with short biological half-life. One method to solve
such  problems  is  to  find  a  dosage  form  capable  of  releasing  the  drug  gradually.
Microencapsulation has been used as one of the methods to deliver drugs in a controlled
manner.
Lamivudine is an analogue of cytidine  which is FDA-approved drug for clinical use for
the treatment  of  HIV infection,  AIDS and AIDS related conditions either alone or in
combination with other antiviral agents. Lamivudine is typically administered orally as a
capsule,  tablet,  and  as  oral  solution.  Lamivudine  is  rapidly  absorbed  after  oral
administration with an absolute bioavailability of 86% ± 16%, peak serum concentration
of lamivudine (Cmax) of 1.5 ± 0.5 mcg/mL and mean elimination half-life (t½) of 5 to 7
hours, thus necessitating frequent administration to maintain constant  therapeutic drug
levels.  Therefore,  the  objective  of  the  present  work  is  to  provide  a  long  acting
pharmaceutical  composition  containing  lamivudine  in  a  sustain  release  matrix
formulation, to maintain the blood levels of the active ingredient for a prolonged period
of time.
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The aim of  this research work was  to  develop and formulate  matrix  tablet  of
Lamivudine  by  using  natural  and  synthetic  polymers,  in  view  to  improve  patient
compliance and therapeutic action. 
The specific objective of this research includes:
1. Ensuring safety and improving patient compliance as well as the efficacy of the
drug;  this can  be achieved  by less  frequent  dosing and better  control  of  drug
plasma levels.
2. Evaluation of the tablets for their hardness, friability, drug content and in vitro
dissolution study.
3. Treatment of dissolution data with various mathematical models.
Plan of work:
1. Preformulation  studies,  to  check  the  compatibility  between  the  drug  and  the
excipients.
2. Design and formulation of matrix tablets of Lamivudine.
3. Evaluation of precompression parameters such as bulk density,  tapped density,
compressibility index etc.
4. Evaluation  of  postcompression  parameters  like  thickness,  hardness,  friability,
drug content and in vitro dissolution.
5. To carry out short term stability studies on the most satisfactory formulation.
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1. Abdul S Althaf,  and study of Lamivudine  oral  sustained release tablets using
hydroxyl propyl methyl cellulose and ethyl cellulose as retardant polymers and to
study the effect of various mixtures of drug and polymers on the release profile of
the formulation. Results concluded that formulation of sustained release tablet of
Lamivudine  containing  80  mg  of  hydroxypropyl-methylcellulose  E15  (high
viscosity grade) and 80 mg of ethylcellulose i.e. formulation F7 can be taken as an
ideal or optimized formulation of sustained release tablets for 16 hours release as
it fulfills all the requirements for sustained release tablet.21 
2. Kar RK et al.,  Design and Characterization of Controlled Release Tablets of
Zidovudine  by  using  various  proportion  of  hydrophilic  polymer  viz  Eudragit
RS100 and  RL 100 along or  in  combination  with  hydrophobic  polymer  ethyl
cellulose and revealed that Eudragit Rs100 or RL 100 10% or 20% w/w of tablet
preparations were able to sustain the drug release up to 9hours, but 30%, 40% as
well as ethyl cellulose combination with 20% and 25% w/w of Eudragit RS100
and RL 100 were able to sustain for 12 hour.22        
3. Sunit  KS  et  al.,  Developed   Microspheres  of  Stavudine  using  copolymers
synthesized  from  acrylic  and  methacrylic  acid  esters  (Eudragit  RS  100  and
Eudragit  RL100) as a retardant material  and concluded that the best-fit  release
kinetics was achieved with Higuchi plot followed by zero order and first order .
The release of Stavudine was influenced by the drug to polymer ratio and particle
size and was found to be diffusion controlled.23 
4. Feleke F et al., formulated  Oral Floating extended release stavudine hydrophilic
matrix tablets by using hydroxy propyl  methyl  cellulose (HPMC) as a release-
modifying  polymer.  NaHCO3  and  Microcrystalline  cellulose  (MCC)  ,grade
Avicel  PH 101, were used as a floating aid release modifier,  respectively and
concluded that   the release rate  was not significantly affected by the levels of
NaHCO3, MCC or CF. Nonetheless, optimum region for the desired drug release 
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was obtained which followed first order at  25% MCC level,  and Korsemeyer-
Peppas model at 40%.24
5. Punna Rao Ravi  et  al.,(2007),  formulated  Lamvudine  oral  controlled  release
tablets by using hydroxy propyl methyl cellulose and concluded that release rate
of the drug from matrix tablets was dependent on proportion as well as viscosity
of HPMC and Lam,  which release  20% to 30% of drug in the first  hour and
extended  the  release  up  to  16  to  20  hours,  can  overcome  the  disadvantages
associated with conventional formulations of Lam.25
6. Sandiip.B.Tiwari  et  al.,(2003),  they  have  prepared  controlled  release  matrix
tablets of  Tramadol  Hydrochloride using Hydrogenated  vegetable  oil,  hydroxy
propyl methyl cellulose, Ethyl cellulose. They studied the effect of concentration
of  Hydrophilic  (Hydroxy propyl  methyl  cellulose)  and  Hydrophobic  polymers
(Hydrogenated castor  oil,  Ethyl  cellulose)  on the release rate  of tramadol was
studied. Hydrophilic matrix tablets were prepared by wet granulation technique,
while Hydrophobic matrix were prepared by melt granulation technique and In-
vitro  dissolution  studies  were  performed  using  united  states  pharmacopeia
apparatus type II. They have concluded that hydrophilic matrix of Hydroxy propyl
methyl cellulose could not control the tramadol release effectively for more than
12 hours. It is evident from the result that a hydrophobic matrix prepared by HCO
is  a  better  system for  controlled delivery  of  a  highly water-soluble  drug  like.
Tramadol  hydrochloride.  The  release  of  coating  with  water-soluble  excipients
(HPMC 6 cps and lactose) proved to be useful as a functional coating to control
the drug release along with masking the bitter taste of the drug.26
7. Basak S C et al, Formulated and studied release behaviour of sustained release
ambroxol hydrochloride HPMC matrix tablet. The results of dissolution studies
indicated that formulation F-V (drug to polymer 1;1.47), the most successful of
the study, exhibited drug release pattern very close to theoretical release profile.
Adecrease in release kinetics of the drug was observed on increasing polymeratio.
Applying exponential equation, all the formulation tablets (except F-V) showed 
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8. K.Raghuram Reddy et  al.,(2003) prepared  sustained release matrix tablets of
nicorandil using HPMC (hydroxyl propyl methyl cellulose), Eudragit RL 100 and
RS 100 and ethyl cellulose, polyvinyl pyrolidine. The tablets were prepared by
wet granulation method the results showed that the hydrophilic matrix of HPMC
alone  could  not  control  the  nicorandil  release  effectively  for  24  hours.  They
observed that the results from matrix tablets prepared with HPMC and granulating
agent of hydrophobic polymer (ethyl cellulose 4%w/v) is a better system for once
daily  sustained  release  of  a  highly  water  soluble  drug  like  nicorandil.
Formulations exhibited diffusion dominated drug release.28
9. Nashiru  Billa  et  al,  studied  the  release  of  drug  from  Xanthan  gum  based
sustained release matrix tablets of diclofenac sodium by using xanthan gum, PEG
6000 and concluded that xanthan gum can be used as an effective matrix former,
to retard the release of diclofenac sodium for extended period of time.29 
10. Corvi  MP et  al,  Developed  Sustained-release  matrix  tablet  formulation  of
Dehydroepiandrosterene  (DHEA)  as  ternary  complex  with  α-cyclodextrin  and
glycine  by  using  the  influence  of  the  swelling  properties  of
hydroxypropylmethylcellulose (HPMC) and the disintegrating power of Explotab
used in combination, as well as the effect of the presence, type and amount of
suitable  channeling  agents  (Emcocel  and  spray  –dried  lactose,  alone  or  in
combination) on drug release behavior from matrix-tablets and concluded that the
best  performances  in  terms  of  drug  release  was  obtained  from  formulations
containing a 75:25 w/w spray-dried lactose: Emcocel combination in the presence
of  HPMC  as  matrix-forming  polymer,  leading  to  a  more  than  65%  DHEA
released at the of the test, a value which was, respectively, 1.9 and 2.7 times 
           higher than those achieved with the corresponding formulations containing spray-
             dried lactose or Emcocel alone.30
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11. Jaber E et al, Formulated  sustain release lithium carbonate matrix tablets and
studied  influence of hydrophilic materials by using different  ratios of polymer
including carbopol (cp), Sodium carboxy methyl cellulose (SCMC) and hydroxyl
propyl methyl cellulose(HPMC) and concluded that release of lithium carbonate
from all formulated sustained matrix tablets were generally sustained. Na CMC,
CP,  and  HPMC  can,  therefore  ,be  used  to  modify  release  rates  of  LC  in
hydrophilic matrix tablets.31 
12. Rangaswamy M et al, Formulated Zolpidem tartarate Extended Release Matrix
Tablets  by using hydrophilic  polymers  like HPMCK-100M, AVICEL PH-102
with  or  without  HPMC K4M and  concluded  that  developed  extended  release
matrix  tablets of Zolpidem tartarate,  capable of maintaining a constant  plasma
concentration throughout the period of 15 hours.32
13. Mutalik  Srinivas  and  Hiremath  Doddayya33  have  worked  on  formulation  and
evaluation  of  chitosan  matrix  tablets  of  nifedipine  matrix  tablets  of  nifedipine
prepared by wet granulation. The in vitro studies showed that the mechanism of drug
release was dominantly diffusion in all the cases.
14. Rangaiah KV et al34  have studied the in vitro drug release rates of sustained release
tablets of theophylline prepared by using eudragits (RLPM and RSPM) and (K15M,
K100M)  as  polymers.  The  drug  release  was  better  approximated  by  first  order
kinetics.
15. Carla Sanchez Lafuente et al,  carried out  Development of sustained release
matrix tablets of didanosine containing methacrylic and ethyl cellulose polymer
was carried out by Carla. The combination of these two polymers have suitably
modulated the release profile of didanosine.35
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16.  Nath  et  al36 formulated  and  evaluated  sustained  release  dosage  forms  of
theophylline using combined hydrophobic and hydrophilic matrix. Cetyl alcohol
and methyl cellulose were used in different proportions i.e. 2:1, 3:1 and 4:1 along
with usual tablet additives, lactose and talc. The matrix component was varied
from 20%, 30% and 40% w/w of total weight. The in vitro release data showed
that  30%  w/w  of  the  total  matrix  component  gave  extended  release  of
theophylline  for  more  than 8h.  Analysis  of  drug  release  rate  from the  matrix
system indicated that the drug was released by anomalous diffusion obeying first
order rate kinetics.
17. Suwannee et al37 studied the swelling properties of hydrophilic cellulose matrix
using three  drugs  having different  water  solubility:  indomethacin,  theophylline
and  mannitol.  Two  swelling  parameters:  maximum  swelling  index  (V)  and
apparent diffusion coefficient of water in the matrix (Dw) were calculated from the
swelling  data.  They    were  used  to  describe  structures  and  properties  of  the
swollen matrix.
18. Mukesh  C.  Gohel  and  Maulik  K.  Panchal38 reported the  method  for  12h
modified  release  tablets  of  diltiazem  hydrochloride  containing  cetyl  alcohol,
alkali-treated  guar  gum,  talc  and  magnesium stearate.  An  in  vitro  dissolution
study was carried out in distilled water. To describe the kinetics of drug release
from the test formulation, various mathematical models were used. The criterion
for selecting the most appropriate model was based on the goodness-of-fit test.
19. Murali GV et al have worked on preparation and evaluation of indomethacin-
ethyl  cellulose polymer  matrix  systems.  Different  ratios  of  indomethacin-ethyl
cellulose polymer matrices were prepared by solvent evaporation technique and
the drug release from tablets was studied. The drug release was found to follow
first order kinetics with diffusion types of release.
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20. Hariharan  et  al formulated  controlled  release  matrix  tablets  of  isosorbide
dinitrate  using  different  polymers  like  carbopol,  HPMC  and  eudragits.  The
influence  of  variables  including  polymer  types,  drug  polymer  ratio,  tablet
hardness, etc. on release profile of isosorbide was discussed. Eudragit NE30D and
carbopol were found to have excellent retarding property.
21. Nagoji  KEV  et  al have  worked  on  release  studies  of  nimesulide  from  ethyl
cellulose and hydroxy propyl methyl cellulose matrices. It  was found that drug
release  from  ethyl  cellulose  matrices  was  slow  when  compared  to  that  from
combined polymer matrices.
22. Singh AV , nath LK et al Evaluation of microwave assisted grafted sago starch
as  controlled  release  polymeric  carrier.  Due  to  this  hardness,  friability,  drug
content and weight variations. 
23. Singh  B,  Garg  B,et  al The  cross  limked  derivative  was  synthesized  with
phosphorous oxchloride and sago starch. The formulated release were evaluated
for various physical characteristecs.
24. Kakubari I , Shinkai N , kawakami J et al , The skin permeability and stability
of formoterol fumarate (FF) in matrix patches using the total of 28 matrix patches
having similar  composition,  containing ethylene-  vinyl  acetate  (EVA).  FF was
found to increase with increasing 1- methonal and NMP contents.  
25. Tsuruta D , S owa J , Tsuruta K et al , Patch testing showed a positive reaction to TSO
(++), gum rosin (++) and wood rosin (++) at 72 h. as TSO includes highly allergenic
material, caution should made in applying this topical therapy.
26. Bhattacharya SS , Mazahir F , Verma A , Ghosh A et al , Microspheres of
xanthan gum (XG) based super absorbent polymer were prepared by water in oil
emulsion  cross  linking  method  of  sustained  release  of  ciprofloxacin
hydrochloride(CIPRO). Based on the result this study suggest that CIPRO loaded
IPN microsphere were suitable for sustained release application
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27. Shiledar  RR  ,  Tagalpallewar  AA  ,Kokare  CR et  al ,  A  novel  bilayered
mucoadhesive buccal patch of zolmitriptan was prepared using xanthan (XG) was
mucoadhesive polymer was used as flim – former and polyvinyl  alchol (PVA)
was incorporate to increase the tensile strength of the patches. In conclusion, XG
can be used as a potential drug release modifier and mucoadhesive polymer for
successful formulation of zolmitriptan buccal pathches.
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3.1 Drug profile
Lamivudine 
Lamivudine  (β-L-2',3'-dideoxy-3'-thiacytidine)(LAM),one  of  the  dideoxycytidine  analogue
Nucleoside Reverse Transcriptase  Inhibitors,  is  the first  nucleoside analogue  approved to
treat chronic HIV infection and AIDS.
Empirical formula: C8H11N3O3S
Molecular weight: 229.26amu
Structure: 
Fig 3:Structure of lamivudine
Description: white to off white crystalline powder.
Bulk density: not less than 0.55gm/cc
Melting point: 160-162oc
Solubility:  Soluble  in  water,  sparingly  soluble  in  methanol,  practically  insoluble  in
acetone.
       
Chemical name:β-L-2',3'-dideoxy-3'-thiacytidine.
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3.1.1 Mechanism of action and resistance
Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of HIV reverse
transcriptase  and also the reverse transcriptase  of  hepatitis  B.  It  is  phosphorylated  to
active metabolites that compete for incorporation into viral DNA. They inhibit the HIV
reverse  transcriptase  enzyme  competitively  and  act  as  a  chain  terminator  of  DNA
synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents
the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation,
and therefore, the viral DNA growth is terminated.
3.1.2Absorption, Distribution, and Elimination
Lamivudine  was  rapidly absorbed  after  oral  administration  in  HIV-infected
patients. Absolute bioavailability in adults is 86% ± 16% for the tablet and 87% ± 13%
for the oral solution.
Lamivudine systemic exposure, as measured by the area under the serum drug
concentration-time  curve  (AUC),  is  not  altered  when  it  is  administered  with  food.
Lamivudine  is  widely distributed into total  body fluid,  the mean apparent  volume of
distribution (Vd) being approximately 1.3 L/kg following intravenous administration. In
pregnant women, lamivudine concentrations in maternal serum, amniotic fluid, umbilical
cord and neonatal serum are comparable, indicating that the drug diffuses freely across
the  placenta.  In  postpartum  women  lamivudine  is  secreted  into  breast  milk.  The
concentration of lamivudine in cerebrospinal fluid (CSF) is low to modest, being 4 to 8%
of  serum concentrations  in  adults  and 9 to  17% of  serum concentrations  in  children
measured at 2 to 4 hours after the dose. In patients with normal renal function, about 5%
of  the  parent  compound  is  metabolised  to  the  trans-sulphoxide  metabolite,  which  is
pharmacologically inactive. 
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In patients with renal impairment, the amount of trans-sulphoxide metabolite recovered in
the urine increases, presumably as a function of the decreased lamivudine elimination. As
approximately 70% of an oral dose is eliminated renally as unchanged drug, the dose
needs to be reduced in patients with renal insufficiency.  Hepatic impairment does not
affect  the  pharmacokinetics  of  lamivudine.  Systemic  clearance  following  single
intravenous  doses  averages  20  to  25  L/h  (approximately  0.3  L/h/kg).  The  dominant
elimination  half-life  of  lamivudine  is  approximately  5  to  7  hours,  and  the  in  vitro
intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to
19 hours in HIV-1 and HBV cell lines, respectively. 
3.1.3 Adverse effects
Abdominal  pain,  nausea,  vomiting,  diarrhoea,  insomnia,  cough,  nasal  symptoms,
arthralgia,  muscle  pain,  headache,  fever,  rash,  alopecia,  malaise,  increased  creatinine
phosphokinase  and  alanine  aminotransferase,  peripheral  neuropathy.  Rarely
rhabdomyolysis,  pancreatitis, hepatitis. Neutropenia and anaemia (in combination with
zidovudine), thrombocytopenia,  increases in LFTs. Paronychia.  Angioedema, urticaria,
and anaphylactoid reaction.
3.1.4 Drug interactions and precautions
Lamivudine is predominantly eliminated in the urine by active organic cationic secretion.
The  possibility  of  interactions  with  other  drugs  administered  concurrently  should  be
considered, particularly when their main route of elimination is active renal secretion via
the organic cationic transport system (e.g., trimethoprim). No data are available regarding
interactions  with other  drugs  that  have renal  clearance mechanisms similar  to that  of
Lamivudine.
Discontinue  use  if  there  is  rapid  increase  in  aminotransferase  levels,  progressive
hepatomegaly,  or  metabolic  or  lactic  acidosis  of  unknown origin.  Discontinue  use  if
clinical  signs,  symptoms  or  lab  abnormalities  suggestive  of  pancreatitis  develop.
Hepatomegaly or other risk factors for hepatic impairment. Monitor hepatic function in
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chronic hepatitis B patients. Exclude HIV infection prior to hepatitis B therapy. Renal
impairment. Pregnancy.
3.1.5 Therapeutic use
Lamivudine has been used for treatment of chronic hepatitis B at a lower dose
than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis
B and also improves histology staging of the liver. 
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3.2 Polymer profile
3.2.1 LOCUST BEAN GUM
 Synonyms:
Algaroba, carob bean gum, carob flour, ceratonia gum, ceratonia siliqua, ceratonia siliqua
gum, Cheshire gum, locust bean gum.
Chemical Name: Carob gum 
Empirical Formula and Molecular Weight:
Ceratonia is a naturally occurring plant material that consists chiefly of a high molecular
weight  hydrocolloidal  polysaccharide,  composed of  D-galactose  and D-mannose units
combined  through  glycosidic  linkages,  which  may  be  described  chemically  as
galactomannan. The molecular weight is approximately 310 000.
Structural Formula:                   
Fig 4: Structure of Locust Bean Gum
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Controlled-release  agent,  stabilizing  agent,  suspending  agent,  tablet  binder,  viscosity-
increasing agent.
 Applications in Pharmaceutical Formulation or Technology:
As a viscosity-increasing agent, ceratonia is said to be five times as effective as starch
and twice as effective as tragacanth. Ceratonia has also been used as a tablet binder and is
used in oral controlled-release drug delivery systems approved in Europe and the USA.
Ceratonia  is  widely  used  as  a  binder,  thickening  agent,  and  stabilizing  agent  in  the
cosmetics and food industry. 
Description:
Ceratonia  occurs  as  a  yellow-green  or  white  colored  powder.  Although odorless  and
tasteless in the dry powder form, ceratonia acquires a leguminous taste when boiled in
water.
Solubility: Ceratonia is dispersible in hot water, forming a sol having a pH 5.4–7.0 that
may be converted to a gel by the addition of small amounts of sodium borate. In cold
water, ceratonia hydrates very slowly and incompletely. 
 Stability and Storage Conditions:
The bulk material should be stored in a well-closed container in a cool, dry place. 
 Incompatibilities:
The viscosity of xanthan gum solutions is increased in the presence of ceratonia. This
interaction is used synergistically in controlled release drug delivery systems.
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Ceratonia  is  generally  regarded  as  an  essentially  noncarcinogenic,  nontoxic  and
nonirritant material. Therapeutically, it has been used in oral formulations for the control
of vomiting and diarrhea in adults and children.
3.2.2 Polymethacrylates
Both Eudragit RS 100 and Eudragit RL 100
Nonproprietary names
• USPNF: Ammonio methacrylate copolymer
• USPNF: Methacrylic acid copolymer
Synonyms
Eudragit; Polymeric methacrylates
Chemical name  
Eudragit  RS  100;  Poly  (ethyl  acrylate,  methyl  methacrylate,  trimethylammonioethyl
methacrylate chloride) 1:2:0.1
Eudragit  RL  100;  Poly  (ethyl  acrylate,  methyl  methacrylate,  trimethylammonioethyl
methacrylate chloride) 1:2:0.2 
Eudragit  RS  and  Eudragit  RL  100  are  also  referred  to  as  ammonio  methacrylate
copolymers, consisting of fully polymerized copolymers of   acrylic acid and methacrylic
acid esters with a low content of quaternary ammonium groups. 
Structural formula
C CH2 CH2C CH2C CH2C
R1 R3 R1 R3
C=O C=O C=O C=O
O
R2
O
R4
O
R2
O
R4
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                         Fig 5: Structure of Eudrgit
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Where, 
Eudragit RL Eudragit RS
R1 = H CH3
R2 = CH3 C2H5
R3 = CH3 CH3
R4 = CH2CH2N(CH3)3+CL- CH2CH2N(CH3)3+CL- 
Functional category
 Film-former; tablet binder; tablet diluents.
Typical properties
Alkalinity:  23.9 – 32.3 for Eudragit RL100, 12.1 – 18.3 for Eudragit RS 100
Density: 0.815 – 0.835 gm/cc for Eudragit RL and RS 100
Refractive index:  ηD20 = 1.38-1.385
Viscosity: ≤ 15 mPa 
Solubility: Soluble in acetone, alcohols, dichloromethane and ethyl acetate        
Stability and storage conditions: Dry powder polymers forms are stable at temperatures
less than 30ºC. Above this temperature, powders tend to form clumps although this does
not affect the quality of the substance and the clumps can be readily broken up.
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 Eudragit RL, RS are used to form water insoluble film coats for sustained release
products.
 Eudragit RL films are more permeable than those of Eudragit RS and by mixing
the two types together films of varying permeability can be obtained.
 Eudragits are also used to form the matrix layers of transdermal delivery systems. 
3.2.3 Rosin Gum
Appearance:-  Trans Parent
Colour:-slight yellow,pale yellow,yellow,deep yellow
Softening Point:- slight yellow,pale yellow-760c
                               yellow,deep yellow-750c
Acid value:- slight yellow,pale yellow-166 mins
                      yellow,deep yellow-165 mins
Alcohol insoluble:- slight yellow,pale yellow-0.03%
                                 yellow,deep yellow- 0.03%
Applications:-Mainly be used as the raw material of adhesives, paints, oil paints, rubber, 
soaps and paper making industries.
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Synonyms: Corn sugar gum, Keltrol, Merezan, Polysaccharide B-1459, Rhodigel
Empirical Formula:
It is a high molecular weight polysaccharide gum. It contains D-glucose and D-
mannose as the dominant hexose unit, along with D-glucuronic acid, and is prepared as
the sodium, potassium, or calcium salt.
Molecular Weight: 2 x 106
Description: Xanthan gum occurs as a cream or white-colored, odorless, free flowing,
and fine powder.
Functional Category: Stabilizing agent, suspending agent, viscosity increasing agent
Applications in Pharmaceutical Formulation:
Xanthan gum is widely used in oral and topical formulations, cosmetics, and food
as a suspending and stabilizing agent. It has also been used to prepare sustained release
matrix tablets.
Solubility: Practically insoluble in ethanol and ether. It is soluble in cold or warm water.
Stability and Storage Conditions:
Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH
range (pH 3-12) and  temperature  between  10-60  °C. Solutions  are  also stable  in  the
presence of enzymes, salts, acids and bases.
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Xanthan  gum  is  generally  regarded  as  nontoxic  and  nonirritant  at  the  levels
employed as pharmaceutical excipients.
Incompatibilities:  Xanthan gum is an anionic material  and is not  usually compatible
with  cationic surfactants,  polymers,  and preservatives  since  precipitation  occurs.  It  is
compatible with most synthetic and natural viscosity increasing agents.
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   3.3 EXCIPIENT PROFILE45
3.3.1 MICROCRYSTALLINE CELLULOSE: 
Synonyms: Avicel, cellulose gel, crystalline cellulose, E460, Emocel, Fibrocel, Tabulose,
Vivacel. 
Functional Category: Tablet and Capsule diluent, suspending agent, adsorbent, tablet
disintegrant. 
Applications:  As  a  diluent  in  tablets  (wet  granulation  and  direct  compression)  and
capsule formulation. In addition to its use as a diluent, it also has some lubricant and
disintegrant property. 
Description: White-colored, odourless, tasteless crystalline powder composed of porous
particles. Available in different particle size grades which have different properties and
applications. 
Solubility: Slightly soluble in 5 % w/v NaOH solution, practically insoluble in water, 
dilute acids and most organic solvents. 
Stability: It is a stable, though hygroscopic material. 
Storage conditions: The bulk material should be stored in a well-closed container in a 
cool, dry, place. 
Incompatibilities: Incompatible with strong oxidizing agents. 
Safety: It is generally regarded as a nontoxic and nonirritant material.
Commercial Grades of Microcrystalline Cellulose 
Grade Nominal Mean Particle Size 
Avicel PH 102 & 112.........................100 µm 
Avicel PH 101 & 103.........................50 µm 
Emocel 50 M......................................51 µm 
Vivacel 102........................................100 µm 
Vivacel 12..........................................180 µm
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Non-proprietary names:
1. BP: Magnesium stearate 
2. JP: Magnesium stearate
3. PhEur: Magnesii stearas 
4. USPNF: Magnesium stearate
Synonyms:
Magnesium octadecanoate, octadecanoic acid magnesium salt and stearic acid 
magnesium salt.
Chemical name:
Octadecanoic acid magnesium salt
Structural formula:
[CH3(CH2)16COO]2Mg
Molecular weight:
591.34
Functional category:
Tablet and capsule lubricant.
Melting point:
117-150°C
Description:
Magnesium stearate is a fine, white, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder
is greasy to touch and readily adheres to the skin.
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It  is practically insoluble in ethanol (95%), ether and water;  slightly soluble in
warm benzene and warm ethanol (95%).
Applications:
It  is  widely  used  in  cosmetics,  foods  and  pharmaceutical  formulations.  It  is
primarily  used  as  a  lubricant  in  the  manufacturing  of  tablets  and  capsules,  in  the
concentration of 0.25-5.0%. It is also used in barrier creams.
Stability and storage conditions:
It should be stored in a well closed container in a cool, dry place.
Incompatibilities:
It is incompatible with strong oxidizing agents, strong acids, alkalis and iron salts.
It cannot be used in products containing aspirin, some vitamins and most alkaloidal salts.
3.3.3 Talc
Non-proprietary names:
1. BP: Purified talc
2. JP: Talc
3. PhEur: Talcum
4. USP: Talc
Synonyms:
Altalc,  Luzenac,  Luzenac  Pharma,  Magsil  Osmanthus,  Magsil  Star,  powdered
talc, purified French chalk, Purtalc, soapstone, steatite and Superiore.
Chemical name:
Talc
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Mg6(Si2O5)4(OH)4
Functional Category:
Anticaking agent, glidant, tablet and capsule diluent and lubricant.
Description:
It  is  a  very  fine,  white  to  grayish-white,  odorless,  impalpable,  unctuous,
crystalline  powder.  It  adheres  readily  to  the  skin and  is  soft  to  touch and  free  from
grittiness.
Solubility:
It is practically insoluble in dilute acids and alkalis, organic solvents and water.
Applications:
It  was  once  widely used in  oral  solid  dosage  formulations  as  a  lubricant  and
diluent. It is widely used as dissolution retardant in the development of controlled release
products. In topical preparations, it is used as a dusting powder, although it should not be
used to dust surgical  gloves.  It  is a natural material; it may frequently contain micro-
organisms and should be sterilized when used as a dusting powder. It is additionally used
to clarify liquids and is also used mainly for its lubricant properties, in cosmetics and
food products.
Stability and storage conditions:
It is a stable material and may be sterilized by heating at 160°C for not less than 1
hour. It  may also be sterilized by exposure to ethylene oxide or gamma irradiation. It
should be stored in a well closed container in a cool, dry, place.
Incompatibilities:
It is incompatible with quaternary ammonium compounds.
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                                         4.0 METHODOLOGY
    4.1 Materials used:     
TABLE NO. 04
S. No.
INGREDIENTS AND
REAGENTS
MANUFACTURER / SUPPLIERS
1. Lamivudine Yarrowchem Products,Mumbai
2. Xanthan Gum Yarrowchem Products,Mumbai
3. Locust Bean Gum Yarrowchem Products,Mumbai
4 Rosin Gum Leochem, Bangalore
5. Eudragit RL 100 Leochem, Bangalore
6. Eudragit RS 100 Leochem, Bangalore
7. PVP K 30 SD Fine chemicals Ltd. Mumbai
8. Magnesium Stearate Loba chemie pvt.ltd, Mumbai
9. Micro Crystalline cellulose SD Fine chemicals Ltd. Mumbai
10. Talc SD Fine chemicals Ltd. Mumbai
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  4.2 Instruments used:     
TABLE NO. 05
Sr.
No.
NAME OF INSTRUMENT MANUFACTURING COMPANY
1. Digital Balance Shimadzu ELB 300
2. Tablet hardness tester Monsanto tablet hardness tester.
3. Friability tester Veego tablet friability test apparatus
4. Vernier Caliper Mitutoyo Corporation, Japan
5. Dissolution apparatus USP XXIII
Electrolab tablet dissolution
apparatus
6.
Double beam UV Spectrophoto-
meter
labindia - 25 UV/VIS spectrometer,
Mumbai.
7. Rotary tablet punching machine
Shakti Pharmatech Pvt.Ltd,
Ahmedabad
8. pH meter Hanna Instruments, Japan
9. FT-IR Spectrophotometer
Perkin Elmer spectrum RX1 FT-IR
spectrometer
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TABLE 6: Pharmacokinetic parameters and its value (for Lamivudine) 
Parameters Value
Bioavailability (F) : 86%
Plasma half life (t1/2) : 5-6 hrs
Concentration at steady state(Css) : 0.44mg/ml
Vol. of Distribution ( Vd) : 1.3 L/KG
Theoretical release profile 
Calculation of Immediate Release profile Lamivudine:
IRP = Css * Vd /F
 Where Css=Concentration at steady state
Vd= Volume of distribution
F= fraction of bio available dose
Calculation of dose
Dose = IRP ([1+0.693t]/ t 1/2)
Where t=time up to sustain release required
t 1/2 = half life of drug 
4.2. DEVELOPMENT OF ANALYTICAL METHOD OF DRUG
Calibration curve of drug Lamivudine was prepared in  phosphate buffer (6.8)
4.2.1. Calibration curve for Lamivudine in phosphate buffer ph 6.8:
4.2.2.
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4.2.2.1. Preparation of phosphate buffer pH 6.8:
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50ml of the potassium dihydrogen  phosphate (0.2M) solution was mixed with
22.4ml of the sodium hydroxide (0.2M) solution in a  volumetric  flask and  then the
volume was made up with water up to 200ml.
4.2.2.2. 0.2M potassium dihydrogen phosphate solution
27.218g of potassium dihydrogen phosphate was dissolved in water and diluted it
with water to make the volume 1000ml.
4.2.2.3. 0.2N NaOH solution
8g of NaOH was dissolved in 1000ml of water.
4.2.2.4. 0.2M KCl solution
14.91g of KCl was dissolved in water, and diluted it with water to 1000ml.
4.2.3. Determination of λmax of Lamivudine in phosphate buffer(PBS) pH 6.8
A solution of Lamivudine in phosphate buffer pH 6.8 was scanned in UV range
between  200  to  350nm (Shimadzu  UV-1601  spectrophotometer,  Japan).  Lamivudine
showed maximum absorbance at 270nm in phosphate buffer pH 6.8.
4.2.4. Preparation of calibration curve in PBS pH 6.8:
Weighed  quantity  of  Lamivudine  (50mg)  was  dissolved  in  little  quantity  (3-5ml)  of
methanol  and  make  up  the  volume  50ml  with  phosphate  buffer  pH  6.8  in  50ml
volumetric flask (SS I).  From SS I,  10ml solution was transferred to 50ml volumetric
flask and volume was made up with PBS pH 6.8 (SS II). From SS II, 10ml solution was
transferred to 50ml volumetric flask and volume was made up with PBS pH 6.8 (SS III).
0.5, 1.0, 1.5, 2.0 and 2.5ml from SS III were transferred to 10ml volumetric flasks and
diluted up to the mark to give 5, 10, 15, 20 and 25µg/ml solutions respectively. 
The absorbance of these solutions was determined in UV spectrophotometer at
270 nm and calibration curve was plotted. 
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Tablet  formulations were prepared by wet granulation method. A non-aqueous
granulation process was adopted to prepare Lamivudine tablets. Granules were prepared
as follows. Proportion of excipients with drug was as given in Table 1. All ingredients
were sifted through sieve no. 40. Xanthan gum,Rosin gum,Locust bean gum ,Eudragit
RL100 and Eudragit RS 100 were mixed with Lamivudine manually and the obtained
blend  was  mixed  with  Micro  crystlline  cellulose  to  form final  blend.  PVPK 30  was
dissolved in PVA (5% w/v) and used for wet granulation of the final blend. The wet mass
was passed through sieve no. 20 and wet granules were dried at 50°C in an oven for 30
minutes. Dried granules were sized by passing it through sieve no. 40 and mixed with
magnesium stearate and talc for 1 minute. Tablets were compressed using Rotary tablet
machine with 10 mm standard concave punch. Tablet weight was (300mg) kept constant
as shown in table-7. 
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TABLE 7: Composition of Factorial Design batchess
Ingredients
(mg/tablet)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24 F25
LAMIVUDINE
(DRUG) 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150
ROSIN GUM 60 75 90 105 120 * * * * * * * * * * * * * * * * * * * *
LOCUST BEAN
GUM * * * * * 60 75 90 105 120 * * * * * * * * * * * * * * *
XANTHAN
GUM * * * * * * * * * * 60 75 90 105 120 * * * * * * * * * *
EUDRAGIT RL-
100 * * * * * * * * * * * * * * * 60 75 90 105 120 * * * * *
EUDRAGIT
RS-100 * * * * * * * * * * * * * * * * * * * * 60 75 90 105 120
AVICEL 76 61 46 31 16 76 61 46 31 16 76 61 46 31 16 76 61 46 31 16 76 61 46 31 16
PVPK-30 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
MAGNESIUM
STERATE 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
TALC 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
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Evaluation Parameters 
4.4.1 Pre Compression Parameters
1. Bulk density (Db)
It is the ratio of powder to bulk volume. The bulk density depends on particle size
distribution, shape and cohesiveness of particles. Accurately weighed quantity of powder
was carefully poured into graduated measuring cylinder through large funnel and volume
was measured which is called initial bulk volume. Bulk density is expressed in gm/cc and
is given by,
                 Db = M / Vo 
Where, Db = Bulk density (gm/cc)
            M is the mass of powder (g)
            Vo is the bulk volume of powder (cc)
2. Tapped density (Dt)
Ten grams of powder was introduced into a clean, dry 100ml measuring cylinder.
The cylinder was then tapped 100 times from a constant height and tapped volume was
read. It is expressed in gm/cc and is given by,
                 Dt = M / Vt 
Where, Dt = Tapped density (gm/cc)
            M is the mass of powder (g)
            Vt is the tapped volume of powder (cc)
3. Angle of repose (θ)
It  is defined as the maximum angle possible between the surface of pile of the
powder and the horizontal plane. Fixed funnel method was used. A funnel was fixed with
its tip at a given height (h), above a flat horizontal surface on which a graph paper was
                                                                                          METHODOLOGY
TABLE 08: Relation between the angle of repose θ, and Carr’s index I of a powder
and its flow characteristics.
CARR’S INDEX (%) TYPE OF FLOW
5-15 Excellent
12-18 Good
18-23 Fair to possible
23-35 Poor
Extremely poor35-38 Very poor
>40
4.4.2 Post Compression Parameters
1. Thickness and diameter
Control of physical dimension of the tablet such as thickness and diameter is essential for
consumer acceptance and tablet uniformity. The thickness and diameter of the tablet was
measured using Vernier calipers. It is measured in mm.
2. Hardness
The Monsanto hardness tester was used to determine the tablet hardness. The tablet was
held between a fixed and moving jaw. Scale was adjusted to zero; load was gradually
increased until the tablet fractured. The value of the load at that point gives a measure of
hardness of the tablet. Hardness was expressed in Kg/cm2.
3. Friability (F)
Tablet strength was tested by Roche friabilator. Pre weighed tablets were allowed for 100
revolutions  (4min),  taken  out  and  were  dedusted.  The  percentage  weight  loss  was
calculated by rewriting the tablets. The % friability was then calculated by,
4. Weight variation
Randomly selected twenty tablets were weighed individually and together in a single pan
balance.  The average  weight  was noted and standard  deviation calculated.  The tablet
passes the test if not more than two tablets fall outside the percentage limit and none of
the tablet differs by more than double the percentage limit.
Table 09: IP standards of uniformity of weight.
Sl.No Average weight of tablet % of deviation
1 ≤ 80 mg 10
2 > 80 mg to <250 mg 7.5
3 ≥ 250 mg 5
Where, PD = Percentage deviation, W
 avg = Average weight of tablet, W initial = individual
weight of tablet. 
5. Uniformity of drug content.
Accurately weighed quantity of the powder tablet equivalent to 100mg of the drug was
transferred to 100ml volumetric flask. 50ml of buffer solution of pH-6.8 was added. Mix
with the aid of ultrasound for 10min, and then the volume was made up to 100ml with the
same buffer solution, mixed solution was filtered through the membrane filter disc with
an average  pore diameter  not greater  than  0.45µm. 5ml of  the filtrate was diluted to
100ml with same buffer solution  and examined under U.V Spectrophotometry at 270nm. 
Table 10:  In-vitro release study.
Apparatus                                                    : USP XXIV Dissolution apparatus
Dissolution medium                                    : Phosphate buffer pH- 6.8
Temperature                                                : 37± 0.5 0 C
RPM                                                            : 50
Vol. withdrawn and replaced                      : 5ml every 1 hour
 λ max                                                          : 270 nm
Blank solution                                             : Phosphate buffer pH- 6.8
Duration of study                                        : 12 hours
900 ml
Volume of dissolution media                   :
Procedure:
In-vitro drug  release  studies  were  carried  out  using  USP  XXII  dissolution
apparatus  type  II  (Electrolab,  Mumbai,  India)  at  50  rpm.  The  dissolution  medium
consisted of 900 ml of pH 6.8 phosphate buffer,  maintained at 37  + 0.50 c. The drug
release  at  different  time  intervals  was  measured  using  an  ultraviolet  visible
spectrophotometer (Labindia, Mumbai, India) at  270 nm. The study was performed in
triplicate.
4.4.3 Kinetic  Analysis  of  In-Vitro  Release  Rates  of  Sustained Release  Tablets  of
Lamivudine49
The results of in vitro release profile obtained for all the formulations were plotted
in modes of data treatment as follows:-
1. Zero – order kinetic model – Cumulative % drug released versus time.
2. First – order kinetic model – Log cumulative percent drug remaining versus time.
3. Higuchi’s model – Cumulative percent drug released versus square root of time.
4. Korsmeyer  equation  /  Peppa’s  model  –  Log cumulative  percent  drug released
1.  Zero order kinetics:
Zero order release would be predicted by the following equation:-
At = A0 – K0t
Where,
At  =  Drug release at time ‘t’.
A0  = Initial drug concentration
K0  = Zero – order rate constant (hr-1).
When the data is plotted as cumulative percent drug release versus time, if the plot is
linear then the data obeys Zero – order release kinetics, with a slope equal to K0.
2.  First Order Kinetics:
First – order release would be predicted by the following equation:-
Log C = log C0 – Kt / 2.303
Where,
C = Amount of drug remained at time‘t’.
C0 = Initial amount of drug.
           K = First – order rate constant (hr-1).
When the data is plotted as log cumulative percent drug remaining versus time
yields a straight line, indicating that the release follow first order kinetics.  The constant
‘K’ can be obtained by multiplying 2.303 with the slope values.
3.  Higuchi’s model:
Drug  release  from  the  matrix  devices  by  diffusion  has  been  described  by
following Higuchi’s classical diffusion equation.
Q = [Dε / τ (2 A - εCs) Cst]1/2
D = Diffusion coefficient of the drug in the matrix.
A = Total amount of drug in unit volume of matrix.
Cs = the solubility of the drug in the matrix.
ε = Porosity of the matrix.
τ = Tortuosity.
τ = Time (hrs) at which ‘q’ amount of drug is released.
Above equation may be simplified if one assumes that ‘D’,  ‘Cs’,  and ‘A’, are
constant.  Then equation becomes:
                                                   Q = Kt1/2 
When the data is plotted according to equation i.e. cumulative drug release versus
square  root  of  time  yields  a  straight  line,  indicating  that  the  drug  was  released  by
diffusion mechanism.  The slope is equal to ‘K’ (Higuchi’s 1963).
4.  Korsmeyer equation / Peppa’s model:
To study the mechanism of drug release from the sustained  release matrix tablets
of Lamivudine, the release data were also fitted to the well  known exponential equation
(Korsmeyer equation / Peppa’s  law equation), which is often used to describe the drug
release behavior from polymeric systems.
Mt / Ma = Ktn
Where,
Mt / Ma = the fraction of drug released at time ‘t’.
K    = Constant incorporating the structural and geometrical characteristics of
the drug / polymer system.
N    = Diffusion exponent related to the mechanism of the release.
Above equation can be simplified by applying log on both sides,
And we get:
                                                Log Mt / Ma  =  Log K + n Log t
release ‘n’ = 0.5 while for anomalous (non – Fickian) transport ‘n’ ranges between 0.5
and 1.0.  The result of in –vitro drug release study of all the formulation as shown below.
            Table 11: Mechanism of Drug Release as per Korsmeyer Equation / Peppa’s 
                             Model           
S. No. N Value Drug release
1. 0.45 Fickian release
2. 0.45 <n <0.89 Non – Fickian release
3. n> 0.89 Class II transport
4.5  FTIR study
FTIR spectra of the selected formulation were taken and compared with the spectrum of
pure drug. The characteristic peaks of drug were checked in the formulation spectra. 
4.6 Stability Studies50
Stability studies of pharmaceutical products were done as per ICH guide lines.  These
studies are designed to increase the rate of chemical or physical degradation of the drug
substance or product by using exaggerated storage conditions.
Method:  Selected formulations were  stored at  different  storage  conditions at  elevated
temperatures such as 25oC± 20C / 60% ± 5% RH, 300C ± 20C / 65% ±5% RH and 400C ±
20 / 75% ± 5% RH for 90 days.  The samples were withdrawn at intervals of fifteen days
and checked for physical changes, hardness, friability, drug content and percentage drug
release.
Table 12: Compatibility studies of  Lamivudine with excipients
Sl.
No Excipients
Drug/
excipients
ratio
Physical
description
initial
300C +  20C / 60%  + 5%
RH
1 week
IR
study
2 week
IR
study
3 week
IR
study
1
Lamivudine --
White
amorphous
powder
* * *
2
Xanthan  Gum --
White
crystalline
powder
* * *
3 Lamivudine
+
Xanthan Gum
1:1 White
amorphous
powder
* * *
4 Lamivudine+Xanthan 
Gum+Avicel+Magnesium
Sterate+Talc
1:1
White
amorphous
powder
* * *
5 Rosin gum Pale yellow
coloured
powder
* * *
6 Lamivudine +Rosin Gum
1:1
Pale yellow
coloured
Powder
* * *
                                                                                                       RESULT    
                                    Figure 6: IR Spectram  of Lamivudine
                                  Figure 7: IR Spectram  of Xanthan Gum
                              Figure 9: IR Spectram  of Formulation F14
                                                                                                       RESULT    
                                  Figure 11: IR Spectram  of Lamivudine + Rosin Gum
Table 13: Calibration curve of Lamivudine in Phosphate Buffer solution (pH 6.8)
SI. No
Co
nc
en
tr
ati
on
(µ
g/
ml
)
Absorbance
1 5 0.030
2 10 0.051
3 15 0.073
4 20 0.095
5 25 0.123
     
The  granular  properties  like  Loose  bulk  density,  Tapped  bulk  density,
Compressibility index  and angle of repose, for the batches F1-F25, were determined and
the results were reported, as shown in tables 14,15,16,17 and 18.
                                                                                                       RESULT    
TABLE :14 Granules properties of formulations F1 to F5 of Lamivudine Sustained 
release Matrix tablets.
Parameters
Formulation code
F1 F2 F3 F4 F5
Angle of repose 25.22 ± 1.32 27.15 ± 1.41 26.22 ± 1.78 29.45 ± 1.52 28.12 ± 1.57
Loose bulk density
(LBD) (g/ml)
0.254 ± 0.005 0.284 ±0.004 0.262 ±
0.003
0.294 ±0.009 0.279 ± 0.006
Tapped bulk 
density (TBD)
(g/ml)
0.273 ± 0.013 0.322 ± 0.011 0.289 ±
0.014
0.235 ±
0.012
0.295 ± 0.016
Compressibility 
index (%)
8.54 ± 0.75 11.63 ± 1.63 9.71 ±  1.33 10.20 ± 1.48 11.56 ± 0.78
TABLE 15:Granules properties of formulations F6 to F10 of Lamivudine Sustained 
release Matrix tablets.
Parameters
Formulation code
F6 F7 F8 F9 F10
Angle of repose  26.12 ± 1.73   31.15 ± 1.38  30.26 ± 1.34   32.35 ± 
1.81
28.23±1.72
Loose bulk density 0.314 ±0.006 0.301 ± 0.001 0.268 ± 0.297 ± 0.284±0.006
                                                                                                       RESULT    
TABLE 16 : Granules properties of formulations F11 to F15 of Lamivudine 
Sustained release Matrix tablets.
Parameters
Formulation code
F11 F12 F13 F14 F15
Angle of repose 25.22 ± 1.32 27.15 ± 1.41 26.22 ± 1.78 27.21±1.54 25.64±1.21
Loose bulk
density (LBD)
(g/ml)
0.254 ± 0.005 0.284 ±0.004 0.262 ± 0.003 0.254±0.002 0.276±0.006
Tapped bulk
density (TBD)
(g/ml)
0.273 ± 0.013 0.322 ± 0.011 0.289 ± 0.014 0.276±0.018 0.296±0.012
Compressibility
index (%)
8.54 ± 0.75 11.63 ± 1.63 9.71 ±  1.33 10.65±1.44 9.94±1.64
TABLE :17 Granules properties of formulations F16 to F20 of Lamivudine 
Sustained release Matrix tablets.
Parameters
Formulation code
F16 F17 F18 F19 F20
Angle of repose 26.22 ± 1.78 29.45 ± 1.52 28.12 ± 1.57 25.64±1.21 27.51±1.37
Loose bulk
density (LBD)
(g/ml)
0.262 ±
0.003
0.294 ±0.009 0.279 ± 0.006 0.276±0.006 0.296±0.004
Tapped bulk
density (TBD)
(g/ml)
0.289 ±
0.014
0.235 ±
0.012
0.295 ± 0.016 0.296±0.012 0.284±0.011
TABLE :18 Granules properties of formulations F21 to F25 of Lamivudine 
Sustained release Matrix tablets.
Parameters
Formulation code
F21 F22 F23 F24 F25
Angle of repose 27.15 ± 1.41 26.22 ± 1.78 27.21±1.54 24.19±1.54 25.20±1.71
Loose bulk
density (LBD)
(g/ml)
0.284 ±0.004 0.262 ± 0.003 0.254±0.002 0.299±0.006 0.324±0.004
Tapped bulk
density (TBD)
(g/ml)
0.322 ± 0.011 0.289 ± 0.014 0.276±0.018 0.276±0.015 0.295±0.019
Compressibility
index (%)
11.63 ± 1.63 9.71 ±  1.33 10.65±1.44 11.23±1.51 10.46±1.31
5.3 POST COMPRESSION PARAMETERS:
TABLE 19: Tablet properties of formulations F1 to F5 of Lamivudine sustained 
release matrix tablets.
Parameters
Formulation code
F1 F2 F3 F4 F5
Thickness (mm) 3.38 ± 0.16 3.48 ± 0.18 3.72 ± 0.32 3.85 ± 0.03 3.61 ± 0.16
Hardness
(kg/cm2)
6.2 ± 0.10 6.7 ±  0.24 6.1 ± 0.14 6.4 ± 0.12 6.83 ± 0.35
Friability (%) 0.29 ± 0.13 0.32 ±  0.41 0.34 ±  0.21 0.28 ± 0.12 0.28 ± 0.35
Drug content (% 98.74 ± 0.235 99.08 ± 0.13 98.90 ± 0.132 98.56 ± 0.136 100.8±0.214
Parameters
Formulation code
F6 F7 F8 F9 F10
Thickness (mm) 3.41 ± 0.14 3.56 ± 0.12 3.92±0.12     3.92±0.12 3.92±0.12
Friability (%) 0.31 ± 0.21 0.33 ± 0.61 0.32 ± 0.41 0.29 ± 0.12 0.63±0.43
Drug content (%) 98.82±0.241 99.06 ±0.14 99.56±0.172 99.42 ±0.154 98.62±0.19
TABLE 21:Tablet properties of formulations F11 to F15 of Lamivudine sustained 
release matrix tablets.
Parameters
Formulation code
F11 F12 F13 F14 F15
Thickness (mm) 3.72 ± 0.32 3.85 ± 0.03 3.61 ± 0.16 3.41 ± 0.14 3.41 ± 0.14
Hardness(kg/cm2) 6.1 ± 0.25 6.6 ± 0.12 6.5±0.14 6.1 ± 0.14 6.4 ± 0.12
Friability (%) 0.32 ±  0.41 0.34 ±  0.21 0.28 ± 0.12 0.32 ± 0.41 0.32 ± 0.41
Drug content (%) 99.30 ±0.172 97.90±0.154 99.49 ± 0.13 98.08±0.132 95.32±0.136
TABLE 22: Tablet properties of formulations F16 to F20 of Lamivudine sustained 
release matrix tablets.
Parameters
Formulation code
F16 F17 F18 F19 F20
Thickness (mm) 3.92±0.12 3.92±0.12 3.92±0.12 3.85 ± 0.03 3.56 ±0.12
Hardness  (kg/cm2) 6.1 ± 0.25 6.6 ± 0.12 6.5±0.14 6.1 ± 0.25 6.6 ± 0.12
Friability (%) 0.29 ± 0.12 0.63±0.43 0.33 ± 0.61 0.34 ± 0.21 0.28 ± 0.12
Drug content (%) 97.63 ± 0.13 95.98 ± 0.132 96.59±0.136 97.49±0.14 98.16±0.172
                                                                                                       RESULT    
TABLE 23:Tablet properties of formulations F20 to F25 of Lamivudine sustained 
release matrix tablets.
Friability (%) 0.33 ±0.61 0.32 ± 0.41 0.63±0.43 0.28 ± 0.12 0.29 ± 0.12
Drug content (%) 98.16±0.132 95.32 ±0.136 98.59 ± 0.136 99.69 ± 0.14 98.96±0.241
                                                                                                       RESULT    
TABLE 24:Weight variation for tablet formulations(F-1 to F-10)
Sl. No F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Wt Wt Wt Wt Wt Wt Wt Wt Wt Wt
6 298 298 299 295 294 302 298 296 299 297
7 299 295 299 296 297 300 299 299 298 297
8 299 300 296 299 301 300 298 297 294 299
9 298 298 298 302 298 298 300 300 298 297
10 298 301 295 300 302 297 301 301 299 302
Average
weight  of
10 tablets
297.5 298.2 296.8 298 298.4 299.2 299.1 299 298.5 298.8
%
Maximum
Positive
deviation
0.5 0.9 0.74 1.34 1.20 0.93 0.63 1.67 0.83 1.07
%
Minimum
Negative
deviation
-1.17 -1.07 -0.94 -1.3 -1.47 -0.73 -0.70 -1.0 -1.5 -0.93
                                                                                                       RESULT    
TABLE 25 :Weight variation for tablet formulations(F-11 to F-20)
Sl. No F11 F12 F13 F14 F15 F16 F17 F18 F19 F20
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
Wt
(Mg)
1 298 298 299 295 294 302 298 296 299 297
2 299 295 299 296 297 300 299 299 298 297
3 299 300 296 299 301 300 298 297 294 299
4 298 298 298 302 298 298 300 300 298 297
5 298 301 295 300 302 297 301 301 299 302
6 302 298 298 298 300 297 300 298 296 298
7 294 297 296 297 299 298 298 297 297 300
8 298 299 300 294 296 299 297 299 298 302
9 297 300 302 297 298 300 298 298 302 299
Positive
deviation
%
Minimum
Negative
deviation
-1.40 -1.23 -1.0 -1.20 -1.30 -0.60 -0.63 -0.90 -1.30 -0.63
                                                                                                       RESULT    
TABLE 26: Weight variation for tablet formulations(F-21 to F-25)
Sl. No F21 F22 F23 F24 F25
Wt     (Mg) Wt  (Mg) Wt   (Mg) Wt (Mg) Wt  (Mg)
1 298 301 295 300 302
2 302 298 298 298 300
3 294 297 296 297 299
4 298 299 300 294 296
5 297 300 302 297 298
6 299 301 297 298 294
7 298 297 298 294 298
8 298 298 294 299 299
9 297 300 297 299 299
10 296 299 298 298 298
Average 
weight 
of 10 tablets
297.7 299 297.5 297.4 298.3
% 
Maximum 
Positive 
deviation
1.44 0.66 1.51 0.87 1.24
% 
Minimum 
Negative -1.24 -0.66 -1.17 -1.14 -1.44
5.4 DRUG CONTENT UNIFORMITY
Table 27: Drug content uniformity of formulations F1-F25
Tablet
formulation
Calculated value
(Mg)
Estimated value
(Mg)
% Of drug content
F1 150 148.12 98.74
F2 150 148.63 99.08
F3 150 148.35 98.90
F4 150 147.85 98.56
F5 150 150.12 100.8
F6 150 148.23 98.82
F7 150 148.60 99.06
F8 150 149.35 99.56
F9 150 149.14 99.42
F10 150 147.94 98.62
F11 150 148.96 99.30
F12 150 146.85 97.90
F13 150 149.24 99.49
F14 150 147.12 98.08
F15 150 142.98 95.32
F16 150 146.45 97.63
F17 150 143.98 95.98
F18 150 144.89 96.59
F19 150 146.24 97.49
F20 150 147.24 98.16
F21 150 147.25 98.16
F22 150 142.98 95.32
F23 150 144.89 96.59
F24 150 149.54 99.69
F25 150 148.45 98.96
5.5 IN-VITRO DISSOLUTION STUDIES
Release studies were carried out in pH 6.8 phosphate buffer (900 ml, 37±0.5 °C, 50 rpm)
for 12 hr using the USP XXIV basket apparatus. At predetermined time intervals, 5 ml of
sample  was  withdrawn,  suitably  diluted  and  spectrophotometrically  assayed  for  drug
concentration at 270 nm. 
Table 28: Percentage drug release of formulations F1-F5
Time
in hr
Formulations
F1 F2 F3 F4 F5
0 0 0 0 0 0
1 22.5±1.8 15.5±1.3 19±2.1 14.5±2.2 16±2.3
2 31.025±1.9 22.017±1.5 24.52±2.6 19.016±2.6 21.01±2.5
3 34.559±2.3 29.541±1.8 28.548±2.4 23.03±2.4 25.54±2.4
4 36.59±2.4 36.074±1.7 33.08±2.3 29.56±2.4 31.06±2.1
5 55.138±1.7 49.614±2.0 39.616±1.8 33.59±2.1 39.10±2.2
6 80.199±1.2 64.169±2.4 46.16±1.4 43.63±2.4 43.64±1.9
7 95.288±1.3 81.74±2.3 55.2116±2.3 55.18±2.5 47.19±1.5
8 --- 96.331±2.5 63.272±2.6 64.23±2.5 59.24±2.3
9 --- --- 78.342±2.1 74.30±1.9 64.81±2.4
10 --- --- 96.429±2.4 82.38±1.6 79.88±2.5
11 --- --- --- 96.97±2.4 89.47±2.4
12 --- --- --- --- 96.57±2.1
                                                                                                       RESULT    
Time
in hr
F6 F7 F8 F9 F10
0 0 0 0 0 0
1 17±2.1 14.5±2.3 14.5±2.3 13.5±2.4 15±2.3
2 26.01±1.8 17.01±2.4 17.51±2.4 17.01±2.1 24.51±2.1
3 36.54±1.4 24.03±1.8 24.53±2.1 23.03±2.4 27.04±2.0
4 49.08±1.7 33.56±1.7 30.56±2.6 34.55±1.9 34.57±2.3
5 64.14±1.9 42.09±1.8 39.59±2.2 38.59±1.8 39.61±2.4
6 74.21±2.3 48.14±2.3 42.64±2.0 46.14±1.9 40.65±2.1
7 89.79±2.1 61.69±2.4 49.18±1.9 50.69±2.3 49.70±2.5
8 97.39±2.2 73.76±2.5 61.24±1.9 61.19±2.4 64.75±2.4
9 --- 96.84±2.4 71.31±1.8 69.26±2.6 73.32±2.6
10 --- --- 84.38±2.3 92.84±2.4 80.90±2.3
11 --- --- 97.98±2.4 96.94±2.2 92.49±2.2
12 --- --- --- --- 96.10±2.3
                                                                                                       RESULT    
Table 30: Percentage drug release of formulations F11-F15
Time
in hr
Formulations
F11 F12 F13 F14 F15
0 0 0 0 0 0
1 17.5±1.9 16±1.8 15.5±2.3 16±2.2 14±2.3
2 24.51±1.8 21.51±1.6 21.51±2.4 21.51±2.1 17.01±2.1
3 35.54±2.3 28.04±2.3 26.04±2.6 28.54±2.3 24.53±2.0
10 --- 98.51±2.5 90.94±2.4 84.91±1.9 82.38±2.1
11 --- --- 98.54±2.3 91.00±1.7 88.47±2.3
12 --- --- --- 98.60±1.8 95.06±1.8
                                                                                                       RESULT    
Table 31: Percentage drug release of formulations F16-F20
Time
in hr
Formulations
F16 F17 F18 F19 F20
0 0 0 0 0 0
1 17±2.1 17±2.3 16.5±1.8 17.5±2.2 18±2.1
2 28.01±2.2 29.51±2.4 24.51±2.1 23.01±1.9 23.52±2.0
3 38.05±2.4 33.55±2.1 34.04±2.3 31.04±1.8 28.54±2.3
4 49.09±2.3 47.08±2.3 39.58±2.2 39.07±2.3 37.57±1.9
5 79.14±2.0 68.14±2.4 47.12±2.1 47.12±2.4 48.61±1.8
6 89.73±1.9 77.21±2.5 59.17±1.9 60.67±2.1 62.67±1.9
7 95.83±1.4 88.30±2.1 68.24±1.5 67.24±2.3 67.24±2.0
8 --- 96.4±1.9 79.32±1.8 79.31±2.1 71.31±2.3
9 --- --- 89.40±1.9 81.40±2.3 79.89±2.0
10 --- --- 97.00±2.3 88.49±2.0 85.98±2.4
11 --- --- --- 95.59±2.1 96.57±2.1
12 --- --- --- --- ---
Table 32: Percentage drug release of formulations F21-F25
Time
in hr
Formulations
F21 F22 F23 F24 F25
0 0 0 0 0 0
1 17.5±1.9 17.5±1.8 14±2.1 16.5±1.8 17±2.1
2 28.01±1.4 35.51±1.4 18.51±1.8 21.01±1.9 21.01±1.8
3 49.00±1.7 45.55±1.5 24.03±1.9 31.04±2.1 26.04±1.7
4 63.60±2.3 58.60±1.7 34.06±2.1 35.07±2.0 30.07±2.3
5 74.67±2.1 65.67±1.6 42.10±2.2 40.61±2.2 36.60±2.2
6 88.75±2.4 78.74±2.1 57.14±1.9 45.66±2.3 43.64±2.0
7 96.85±2.1 91.83±2.2 67.21±2.0 59.71±2.4 49.19±2.2
8 --- 97.93±1.5 77.78±2.4 70.77±2.6 59.24±2.4
9 --- --- 88.37±2.2 77.35±2.3 74.31±2.1
10 --- --- 96.96±2.3 88.44±2.1 80.39±2.0
11 --- --- --- 96.03±1.9 89.98±1.8
12 --- --- --- --- 94.58±2.3
                                                                                                       RESULT    
Figure 13:In-vitro dissolution of F1 to F10 formulations
Figure 14: In-vitro dissolution of F11 to F20 formulations
Figure -15: In-vitro dissolution of F21 to F25 formulations
The results of kinetic treatment applied to dissolution profiles of tablets of F5 and F14
were determined and shown as follows
Table 33:Model fitting for formulation F-5(Rosin Gum)
Time(hrs) %CDR Log of %drug
unreleased
Log time SQRT Log%CDR
1 16 1.924279 0 1 1.204119983
2 21.01778 1.897529 0.301029996 1.414213562 1.322585189
3 25.54111 1.871917 0.477121255 1.732050808 1.407239767
4 31.06944 1.838412 0.602059991 2 1.492333426
5 39.10389 1.78459 0.698970004 2.236067977 1.592219963
6 43.64722 1.750915 0.77815125 2.449489743 1.639956588
7 47.19556 1.72267 0.84509804 2.645751311 1.673901144
8 59.24778 1.610151 0.903089987 2.828427125 1.772672082
9 64.81333 1.546378 0.954242509 3 1.811664335
10 79.885 1.30352 1 3.16227766 1.90246524
11 89.47333 1.022291 1.041392685 3.31662479 1.951693601
12 96.57222 0.535013 1.079181246 3.464101615 1.984852215
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Figure 16:Zero order approximation for the formulation F5
                     Figure 17 :First order approximation for the formulation F5
                 Figure 19 :Korsmeyer-Peppas approximation for the formulation F5
Table 34:Model fitting for formulation F-14(Xanthan Gum)
Time(hrs) %CDR Log of
%drug
unreleased
Log time SQRT Log%CDR
1 16 1.924279 0 1 1.204119983
2 21.51778 1.894771 0.301029996 1.414213562 1.332797463
3 28.54167 1.854053 0.477121255 1.732050808 1.455479381
4 34.07333 1.819061 0.602059991 2 1.532414579
5 38.61111 1.78809 0.698970004 2.236067977 1.586712287
6 44.65389 1.743087 0.77815125 2.449489743 1.649859298
7 49.20333 1.705835 0.84509804 2.645751311 1.691994496
8 64.25778 1.553182 0.903089987 2.828427125 1.807925717
9 74.32889 1.409445 0.954242509 3 1.871157647
10 84.91111 1.178657 1 3.16227766 1.928964518
11 91.005 0.954001 1.041392685 3.31662479 1.959065254
12 98.60556 0.144401 1.079181246 3.464101615 1.993901404
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                    Figure 20 :Zero order approximation for the formulation F14
                     Figure 22 :Higuchi’s approximation for the formulation F14
              Figure 23: Korsmeyer-Peppas approximation for the formulation F14
Formulations
Zero order plots◘
First order 
plots▪
Higuchi’s 
plots●
Korsmeyer et
al’s plots□
F1 0.8989 0.7293 0.820 0.8459
F2 0.966 0.748 0.9027 0.948
F3 0.9403 0.748 0.8641 0.9097
F4 0.9747 0.7229 0.9097 0.9386
F5 0.9744 0.7648 0.9128 0.9476
F6 0.9956 0.834 0.9688 0.9876
F7
0.951 0.6463 0.881 0.9324
F8 0.9676 0.6624 0.9023 0.9473
F9 0.9638 0.6528 0.9046 0.9562
F10 0.9752 0.8124 0.9209 0.9545
F11 0.9908 0.8004 0.9613 0.9758
F12 0.9771 0.6463 0.9332 0.9511
F13 0.9798 0.7708 0.9273 0.9496
F14 0.980 0.7373 0.9253 0.9566
F15 0.9792 0.8209 0.9266 0.9604
F16 0.9684 0.8949 0.9398 0.9720
F17 0.9844 0.8742 0.9601 0.9759
F18 0.9952 0.816 0.9596 0.9838
F19 0.9907 0.896 0.9731 0.9785
F20 0.9887 0.8299 0.9683 0.9688
F21 0.9881 0.8912 0.9398 0.972
F22 0.9908 0.8464 0.9909 0.9937
F23 0.9885 0.8102 0.9414 0.9594
F24 0.9843 0.8112 0.9346 0.9597
F25 0.9769 0.839 0.9163 0.9342
                                                                                                       RESULT    
 
 
◘Zero order equation, C=K0 t.              ▪First order equation, LogC=logCₒ-Kt/2.303.
   ●Higuchi’s equation, Q= Kt½.               □Korsmeyer et al’s equation, Mt/Mα= Ktn.
5.7 Stability Studies
250C± 20C / 60% ± 5%
RH
No change Physical appearance
350C± 20C / 60% ± 5%
RH
400C± 20C / 60% ± 5%
RH
Table 37: Hardness of optimized formulations after stability studies
No. of
days
F5 F14
Hardness (Kg/cm2)* Hardness (Kg/cm2)*
250C /
60% RH
300C /
65% RH
400C /
75% RH
250C /
60% RH
300C /
65% RH
400C /
75% RH
0 6.8  6.8  6.8  6.1  6.1  6.1
15 6.8  6.8   6.8   6.1   6.2  6.1
30 6.7  6.7  6.9  6.1  6.2  6.2
45 6.7  6.7  6.7  6.2  6.1  6.2
60 6.6  6.7  6.7  6.2  6.2  6.2
75 6.6  6.6  6.8  6.2  6.2  6.3 
90 6.6  6.7  6.8  6.1  6.2  6.3
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Table 38: Friability of optimized formulations after stability studies
No. of
days
F5 F14
60 0.30 0.31 0.38 0.34 0.33 0.38
75 0.29 0.29 0.36 0.35 0.35 0.36
90 0.33 0.35 0.40 0.39 0.38 0.41
Table 39: Drug content of optimized formulations after stability studies
No. of
days
F5 F14
Drug content (mg) Drug content (mg)
250C /
60% RH
300C /
65% RH
400C /
75% RH
250C /
60% RH
300C /
65% RH
400C /
75% RH
0 98.10 98.15 97.78 98.80 98.31 98.22
15 97.15 97.20 97.13 98.20 98.24 98.18
30 97.22 97.17 97.20 98.16 98.17 98.14
45 97.18 97.15 97.18 98.21 97.19  98.26
60 97.11 97.10 97.08 98.15 98.16 97.20
75 97.08 97.12 97.02 98.08 98.09 98.01
90 97.10 97.08 96.91 98.10 98.00 98.55
Table 40: Percentage drug release from optimized formulations after stability 
studies
No. of
days
F5 F14
% Drug release % Drug release
250C /
60% RH
300C /
65% RH
400C /
75% RH
250C /
60% RH
300C /
65% RH
400C /
75% RH
0 96.50 96.45 95.20 97.90 98.10 97.94
15 96.26 95.19 96.96 98.09 97.11 97.84
30 96.69 94.55 95.75 97.16 97.94 97.06
45 95.94 94.87 95.17 97.39 97.21 98.11
60 95.77 93.91 96.09 98.22 98.05 96.77
75 94.85 94.37 96.93 97.94 97.83 97.85
90 93.75 95.88 94.65 97.98 96.91 97.62
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                                            6.0 DISCUSSION
good patient compliance. The main advantage of the oral sustained release dosage form is
that it maintains the therapeutic concentration over an extended period of time.
Several  new technologies  have been developed to overcome the physicochemical  and
pharmacokinetic characteristic of drugs, while improving the patient compliance. One of
these technologies is the matrix type of dosage forms.
6.1 Drug Selection
  Lamivudine (β-L-2',3'-dideoxy-3'-thiacytidine)(LAM),one of the dideoxycytidine
analogue  Nucleoside  Reverse  Transcriptase  Inhibitors,  is  the  first  nucleoside  analogue
approved to treat chronic HIV infection and AIDS.  Lamivudine is typically administered
orally as a capsule, tablet, and sustained released tablet and as oral solution.  Conventional
oral formulations of LAM are administered multiple times a day (150 mg  per dose) because
of its moderate half-life (t1/2 = 5-7 hours).Treatment of AIDS using conventional formulations
of  LAM is  found  to  have  many drawbacks,  such  as  adverse  side  effects  resulting  from
accumulation  of  drug  in  multi-dose  therapy,  poor  patient  compliance,  and  high  cost.
Controlled release formulations of LAM can overcome some of these problems. This study,
therefore, aims to find out the influence of natural and synthetic polymers on formulation
and evaluation of Lamivudine matrix tablet.
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processes required, level of reproducibility, stability of the raw materials and dosage form
as well as ease of scale up operation, validation and favorable in-vitro in-vivo correlation 
Classically  simple  matrix  delivery  systems  exhibit  first  order  or  square  root  of  time
release kinetics. Matrix tablets are resistant to dose dumping. Due to the simple nature of
the formulation and being robust they are unaffected by variations in ingredients. Matrix
tablets containing acrylic polymers are common and commercially successful means of
prolonging oral drug delivery and hence patient compliance.
 6.3 Matrix Tablets
XanthanGum,RosinGum,Locust BeanGum,Eudragit RL100, Eudragit RS100,Avicel,Talc
and  Magnesium  Sterate  Were  Chosen  for  the  Formulations.Xanthan  Gum  is  a  non
toxic,hydrophilic nature,cost effective and also reduces the risk of systemic toxicity due
to dose dumping.
Rosin  Gum  also  nontoxic,  non-allergic  hydrophilic  nature,cost  effective  ,and  easily
available.
Locust Bean Gum also having same properties like Rosin Gum and Xanthan gum but it is
costly compare with Xanthan and Rosin Gum 
Eudragit  RL100  and  Eudragit  RS100  also  non  toxic,  non  allergic,  non  irritating
biocompatible, soluble at pH higher than 6.5. 
6.4   Melting Point Determination
Milting point was found to be 160-162ºC and it is within the range specified in the official
limits.
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6.5 Compatibility Study
Drug –excipients compatibility studies were carried out at an accelerating condition of
300C+20C / 60%+ 5% RH. A small quantity of each mixture was evaluated by FTIR
(figure-06,07,08,09,10,11) with the control i.e the pure Lamivudine and the excipient was
studied. It was found that all peaks corresponding to different functional groups of pure
drug were present in the drug-excipient mixture, this shows the absence of interaction
between the drug and excipients listed in Table: 12. 
6.6 Flow Properties                       
A  flow  property  plays  an  important  role  in  pharmaceuticals  especially  in  tablet
formulation because improper flow may cause more weight variation. Values of Carr’s
Index (Compressibility) below 15% usually give rise to good flow properties but readings
above 25% indicate poor flow properties. It was found that the compressibility values of
the powders were below 15% and hence they exhibit good flow characteristics.
Values of angle of repose are rarely 20o  and values up to 40o  indicate reasonable flow
properties. Above 50o  however the powder flows only with great difficulties. Dynamic
angle  of  repose  measurements  can  be  replicated  with  relative  standard  deviations  of
approximately 2%. They are particularly sensitive to changes in particle size distribution
and to the moisture content, and they provide a rapid means of monitoring significant
batch to batch differences in these respects.
The  Carr’s  Index  (Compressibility)  of  the  powders  was  in  the  range  of  8.54  ± 0.75
to11.63 ± 1.63. The angles of repose of the powders were in the range of 24.19 ± 1.540 to
32.35 ± 1.810, which indicate a good flow property of the powders. Here the angle 
of repose was found to be below 40o this shows that the reasonable flow property of
powders.
The punches used to compress the tablets were 10.00mm, spherical shaped. The shape
and size of the tablets were found to be within the limit. The hardness of the tablets was
found to be in the range of 6.1 ± 0.14 to 6.83 ± 0.35 Kg/ cm2. It was within the range of
monograph specification. 
Thicknesses of the tablets were found to be in the range of 3.38 ±0.16 to 3.92 ± 0.12mm.
The friability of the tablets was found to be less than 1% and it was within the range of
standard specification. 
6.7.2 Weight Variation and Drug Content
Weight variation test helps to check whether  the tablet contain proper quantity of the
drug.  From each of the formulations twenty tablets were randomly selected and weighed.
The results are given in table 24 to 26. The average weights of the tablets were found to
be within the prescribed official limits (IP).
Drug content for each of the formulations were estimated. The drug content for all the
batches were found to be in the range of 95.32 ± 0.241 to 100.8 ± 0.13 %. The results are
given in table 27.
6.7.3 In-Vitro Release Study:
In vitro release studies were carried out for all the formulations as per USP XXIV tablet
dissolution tester employing basket at 50rpm using 900ml of phosphate buffer of pH 6.8
as  dissolution  medium.  The  results  were  evaluated  for  12hrs.  As  per  the  results  of
dissolution study formulations F1,F2,F3,F4,F5,F6,F7,F8,F9,F10,F11,F12,F13,F14,F15, 
F16,F17,F18,F19,F20,F21,F22,F23,F24andF25  showed  95.288  ±  1.3,  96.331±2.5,
96.429±2.4,96.97±2.4,96.57±2.1, 97.39±2.2,96.84±2.4,97.98±2.4,96.94±2.296.10±2.3,
98.90±2.0,98.51±2.5,98.54±2.3, 98.60±1.8,95.06±1.8,95.83±1.4,96.40±1.9,97.00±2.3,95.
59±2.1,96.57±2.1,96.85±2.1,97.93±1.5,96.96±2.3,96.03±1.9,94.58±2.3%
98.60% release within 12hr.  Where as in formulation F1 containing 20% of Rosin gum
showed 95.28 ± 1.3% of drug release was noted in 7 hours. From the above results it was
found that the drug release was sustained with the increase in the polymer concentration.
The lamivudine matrix tablets prolonged drug
release  for  12  hours  or  longer  would  be  capable  of  reducing  the  frequency  of
administration  and  the  dose-dependent  side  effects  associated  with  the  repeated
administration  of  conventional  lamivudine   tablets.  No drug  polymer  interaction  was
found and lamivudine remained stable over a long period of time.
Formulations F5 and F14 were found to be most promising formulations as they showed
sustained release (96.57± 2.1 and 98.60± 1.8%) as well as maintained excellent matrix
integrity  during the period of  study (table 28 to 32 and figure  13-15).  Also all  other
parameters like hardness, thickness, friability, drug content and weight variation for these
formulations were within the range. So, formulations F5 and F14 were selected as the
optimized formulations.
6.8 Kinetics:
Different models like Zero order, first order, Higuchi’s, and Peppas plots were drawn.
The regression coefficient ( R2) value for Zero order, First order, Higuchi’s, and Peppas
plots (figure 16-23 and table 35) for formulation F5 were found to be 0.9744, 0.7648,
0.9128, 0.9476 and for formulation F14 were found to be 0.980, 0.7373, 0.9253, 0.9566.
The optimized formulations F5and F14 follows Higuchi’s plot since the regression 
coefficient is 0.9128 and 0.9253 and plots were also found to be linear, this confirms that
the drug release through the matrix was diffusion.
no  noticeable  incompatibility  between  the  drug  and  excipients  in  the  selected
formulations.
6.10 FTIR Spectroscopy:
Drug polymer interaction was checked by comparing the IR spectra of the formulations
with the IR spectra of the pure drug. There was no significant change in the functional
groups between the IR spectrum of the pure drug and also no additional peaks were seen
in the selected formulations (figure 6,7,8,9,10 and 11). This confirms that no interaction
between drug and excipients.
6.11 Stability Study :
Stability  studies  were  carried  out  on selected  formulations  (F5  and  F14)  as  per  ICH
guidelines.  There  was not  much variation  in  matrix integrity  of  the  tablets  at  all  the
temperature  conditions.  There  was  no  significant  changes  in  drug  content  ,  physical
stability, hardness, friability and drug release (table 36-40)for the selected formulations
F5 and F14 after 90 days at 25oC± 20C / 60% ± 5% RH, 300C ± 20C / 65% ±5% RH and
400C ± 20 / 75% ± 5% RH.
Therefore the main objective of the study to formulate and evaluate the matrix tablets of a
model antiviral drug using Rosin gum and xanthan gum as a retardant were achieved.
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7.0 CONCLUSION
In this study matrix tablet of Lamivudine  was prepared by wet granulation technique,
using Rosin gum, Xanthan gum, Locust bean gum, Eudragit RL 100 and Eudragit RS 100
polymers alone as retardant. It was found that increase in the concentration in polymeric
ratio decreases the drug release and able to sustain for 12 hours. The formulation F5 and
F14 containing 40% of Rosin gum , 35% of Xanthan gum showed good drug release with
good matrix  integrity.  Different  parameters  like  hardness,  friability,  weight  variation,
drug content uniformity, in-vitro drug release etc. were evaluated for these formulations.
Based on these results formulations F5 and F14 were found to be the most promising
formulations. The optimized formulations F5 and F14 follows Higuchi’s plot since the
regression coefficient is 0.9128 and 0.9253 and plots were also found to be linear, this
confirms that the drug release through the matrix was diffusion. Stability studies were
conducted for the optimized formulations as per ICH guidelines for a period of 90 days
which revealed the stability of the formulations. The results suggest that the developed
sustained-release tablets of lamivudine could perform better than conventional dosage
forms, leading to improve efficacy and better patient compliance. Thus the aim of this
study was achieved. Further preclinical and clinical studies are required to evaluate the
efficacy of these formulations of Lamivudine in the management of HIV. 
                                                                                                      SUMMARY
8.0 SUMMARY
The aim of the present  work  was  to  formulate  and  to evaluate  the  matrix  tablets  of
Lamivudine  by wet granulation technique with a view to sustain the drug release and to
enhance the stability.  Hence frequency of drug administration was reduced and better
patient compliance was achieved.
Lamivudine is a freely water soluble drug which is used in the treatment of HIV. In early
monotherapy trials, Lamivudine reduced plasma HIV RNA by 70% to 90% and delayed
disease progression compared with continued zidovudine therapy. Lamivudine improves
the  long-term virologic  response  to  stavudine,  possibly reflecting  the  benefits  of  the
M184V mutation. Many large prospective clinical trials have demonstrated potent and
durable  suppression  of  viremia  and  sustained  increases  in  CD4+  cell  counts  when
lamivudine  is  combined  with  other  nucleoside  analogs  plus  NNRTIs  or  protease
inhibitors. The drug therefore remains a common component of antiretroviral regimens.
Based on the drug information and physicochemical properties of drug it was found that,
the drug is suitable for developing the sustained release matrix dosage form.
25 different formulations were prepared by wet granulation method using  Rosin gum,
Xanthan gum, Locust bean gum, Eudragit RL 100 and Eudragit RS 100 as retardant alone
with increasing polymer concentration. Talc was used as glidant.
Characterization of the drug was done by Performing the melting point, UV spectroscopy
and IR spectroscopy. IR spectrum of the pure drug was compared with that of physical
mixture of drug with all the excipients used in the study. The results showed that there
was no drug-excipient interaction. The melting point was found to be 160-1620C and
from the UV spectral analysis of the drug solution indicated that λmax value as 270nm.
Pre compression and carr’s index of the pure drug indicated that the drug had good flow
                                                                                                      SUMMARY
 The thickness of the formulations (F1-F25) was in the range of 3.38 ±0.16 to 3.92 ±
0.12mm and the hardness was in the range of 6.1 ± 0.14 to 6.83 ± 0.35 Kg/ cm2, indicated
good mechanical strength of the tablets. Friability and drug content uniformity was found
to be within official limits for all the formulations. 
The dissolution studies were carried out for 12hrs. As per the result of dissolution study
formulation F5 and F14 showed good drug release profile (96.57 ± 2.1 and 98.60 ± 1.8%)
and they showed excellent matrix integrity during the period of study, when compare to
other formulations. 
Based  on  all  these  results,  formulations  F5  and F14  were  selected  as  the  optimized
formulations with 96.57 ± 2.1 and 98.60 ± 1.8% drug release. The release kinetics was
fitted to different mathematical models like Zero order, First order, Higuchi’s and Peppas
plot. The optimized Formulations F5 and F14 follows Higuchi’s plot since the regression
coefficient is 0.9128 and 0.9253 and plots were also found to be linear; this confirms that
the drug release through the matrix was diffusion.
The drug polymer interaction of the optimized formulations was evaluated by TLC and
FTIR. FTIR spectrum of pure drug was compared with that of formulations F5 and F14.
All peaks corresponding to the different functional groups of pure drug were present in
the  formulations  which  indicate  the  absence  of  interaction  between  the  drug  and
excipients.
The selected formulations (F5 and F14) were subjected for stability studies as per ICH
guidelines. Formulations subjected for stability studies were checked for drug content,
hardness, friability and physical appearance for 90 days with an interval of 15 days. The
formulations were found to be stable as no significant change was observed in the various
evaluated parameters of the formulations.
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